CA2340589A1 - Toxicological response markers - Google Patents

Abstract

The present invention relates to a composition comprising a plurality of nucleic acid molecules. The composition can be used as hybridizable array elements in a microarray. The present invention also relates to methods for screening compounds and therapeutics for metabolic responses indicative of a toxic compound.

Description

TOXICOLOGICAL RESPONSE MARKERS

This application is filled under the Patent Cooperation Treaty and claims the benefits of U.S. Nonprovisional Application No. 09/141,825, our Docket No. PA-0010 US, filed on August 28, 1998, U.S: Nonprovisional Application No. 091172,711., our Docket No. PA-0011 US, filed on October 13, 1998, andU.S. Nonprovisional Application No. 09/172,108, our Docket No. PA-0012 US, ftIed on October 13, 1998.
TECHNICAL FIELD
The present invention relates to compositions and methods for use in detecting metabolic i0 and toxicological responses.
BACKGROUND ART
Toxicity testing is a mandatory and time-consuming part of the pharmaceutical drug development pipeline. A more rapid screen to determine the effects upon metabolism and to detect toxicity of lead drug candidates may be the use of gene exjpression microarrays. For examlile, IS microarrays of various kinds may be produced using full length genes or gene fragments. These arrays can then be used to test samples treated with the drug candidates to elucidate the gene expression pattern associated with drug treatment. This gene pattern can be compared with gene expression patterns associated with compounds which produce known toxicological and metabolic responses.
20 Benzo(a)pyrene is a known rodent and likely hutr~an carcinogen and is the prototype of a class of compounds, the polycyclic aromatic hydrocarbons (PAH). It is metabolized by several forms of cytochrome P450 (P450 isozymes) and associatf;d enzymes to form both activated and detoxified metabolites. The ultimate metabolites are the !bay-region diol epoxide, benzo(a)pyrene-7,8-diol-9,10-epoxide (BPDE) and the K-region diol epoxide, 9-hydroxy benzo(a)pyrene-4,S-25 oxide, both of which induce formation of DNA adducts. DNA adducts have been shown to persist in rat liver up to 56 days following teeatment with benzo( a)pyt'ene at a dose of 10 mg/kg body weight three times per week for two weeks (Qu and Stacey (1996) Carcinogenesis 17:53-59).
Acetaminophen is a widely-used analgesic. It is metabolized by specific cytochrome P450 isozymes with the majority of the drug undergoing detox:iftcation by glucuronic acid, sutfate and 30 glutathione conjugation pathways. However, at suprathe;rapeutic doses, acetaminophen is metabolized to an active intermediate, N acetyl p-benzoquinone imine (NAPQI) which can cause hepatic and renal faiiure. NAPQI then binds to sulfhydryl groups of proteins causing their inactivation and leading to subsequent cell death (Kroger et al. ( 1997) Gen.
Pharmacol. 28:257-263 ).
35 Clofibrate is an hypolipidemic drug which lowers elevated levels of serum triglycerides.
-i-In rodents, chronic treatment produces hepatomegaly and am increase in hepatic peroxisomes.
Clofibrate has been shown to increase levels of cytochrome; P450 4A and reduce the levels of P450 4F. It is also involved in transcription of (i-oxidation genes. as well as induction of peroxisome proliferator (PP) activated receptors (Kawashima et al. (1997) Arch. Biochem.
Biophys. 347:148-154). Peroxisome proliferation that is induced by both c1o1:7brate and the chemically-related compound fenofibrate is mediated by a common inhibitory effect on mitochondria) membrane depolarization (Zhou and Wallace (1999) Toxicol. Sci. 48:82-89).
The present invention provides compositions and methods for the screening of compounds for metabolic and toxicological responses.
DISCLOSURE OF iNVF;NTION
The invention provides nucleic acid molecules whose transcript levels are modulated in a sample during a metabolic response to a toxic compound. The invention also provides nucleic acid molecules whose transcript levels are upregulated in a sample during a metabolic response to a toxic compound. The invention also provides nucleic acid molecules whose transcript levels are downregulated in a sample during a metabolic response to~ a toxic compound.
Upregulation or downregulation is at least 2 fold, more preferably at least :2.5 fold, most preferably at least 3 fold.
The metabolic response to a toxic compound may be a toxicological response.
In another aspect, the invention provides a method for screening a compound for a metabolic response to a test compound or molecule. The method comprises treating a tissue with a known toxic compound, determining levels of a plurality of nucleic acid molecules, selecting from the plurality of nucleic acid molecules those nucleic acid molecules that have levels modulated in samples treated with known toxic compounds when compared with untreated samples. Some of the transcript levels may be upregulated by a toxic compound, others may be downregulated by a toxic compound, and still others may be upregulated with one known toxic compound and be downregulated with another known toxic compound. The selected nucleic acid molecules which are upregulated and downregulated by a known toxic connpound are arrayed upon a substrate. The method further comprises determining levels of nucleic acid molecules in a sample after the sample is treated with a compound. Levels of nucleic acrid molecules in a sample so treated are then compared with the plurality of the arrayed nucleic acid molecules to identify which sample nucleic acid molecules are upregulated and downregulated by the compound.
Preferably, the comparing comprises contacting the arrayed nucleic acid molecules with the sample nucleic acid molecules under conditions effective to form hybridization complexes between the arrayed nucleic acid molecules and the sample nucleic acid molecules; and detecting the presence or absence of the hybridization complexes. In this context, similarity may mean that at least 1, preferably at least 5, more preferably at least 'l0, of the upregulated arrayed nucleic acid molecules form hybridization complexes with the sample nucleic acid molecules at least once during a time course to a greater extent than would the probes derived from a sample not treated with the test compound or a known toxic compound. Similarity may also mean that at least 1, preferably at Ieast~3, of the downregulated arrayed nucleic acid molecules form hybridization complexes with the sample nucleic acid molecules at least once during a time course to a lesser extent than would the sample nucleic acid molecules of a sample not treated with the test compound or a known toxic compound.
Preferred tissues are selected from the group consisting of liver, kidney, brain, spleen, pancreas and lung. Preferred toxic compounds are selected from the group consisting of hypolipidemic drugs, n-alkylcarboxylic acids, n-alkylcarboxylic acid precursors, azole antifungal compounds, leukotriene D4 antagonists, herbicides; pesticiides, phthalate esters, phenyl acetate, dehydroepiandrosterone sulfate, oleic acid, methanol and their corresponding metabolites, acetaminophen and its corresponding metabolites, benzo(ai)pyrene, 3-methylcholanthrene, benz(a)anthracene, 7, I2-dimethylbenz(a)anthracene, their corresponding metabolites, and the like.
I S The arrayed nucleic acid molecules comprise fragments of messenger RNA
transcripts of genes that are up-regulated or down-regulated at least 2-fold, prc;ferably at least 2.5-fold, more preferably at least 3-fold, in samples treated with known toxic compounds when compared with untreated samples. Preferred arrayed nucleic acid molecules are selected from the group consisting of SEQ ID NQs:1-117, or fragments thereof, some of whose levels are upregulated and others of whose levels are downregulated. More preferable are SEQ ID NOs: 3, 9, 10, 13, 19, 26, 3I, 33, 35, 36, 37, 39, 42, 57, 67, 78, 81, 82, 94, and 98 which are upregulated, and SEQ ID NOs:
43, 49, 50, 52; 53, 54, 55, 56, 59, 61, 63, 68, 71, 74, 85, 87, 90, 95, 102, I03, I05, and 115 which are downregulated. Most preferable are SEQ ID NOs: 31., 33, 35, 36, 39, 52, 53, 54, 55, 63, 74, 81, 90, 94, and 95. In one embodiment, the polynucleotide targets are hybridizable array elements of a microarray.
Alternatively, the invention provides methods for screening a test compound or molecule fox a metabolic response or for screening a sample for a metabolic response to a test compound or molecule.
Alternatively, the invention provides methods for screening a test compound or molecule for a previously unknown metabolic response or for screening a sample for a previously unknown metabolic response to a test compound or molecule.
In another aspect, the invention provides methods for preventing a toxicological response by administering complementary nucleotide molecules against one or more selected upregulated nucleic acid molecules or a ribozyme that specifically cleaves such molecules.
Alternatively, a toxicological response may be prevented by administering sense nucleotide molecules for one or more selected downregulated nucleic acid molecules.
In yet another aspect, the invention provides methods for preventing a toxicological response by administering an agonist which initiates transcription of a gene comprising a downregulated nucleic acid molecule of the invention. Alternatively, a toxicological response may be prevented by administering an antagonist which prevents transcription of a gene comprising an upregulated nucleic acid molecule of the invention.
The invention also provides a substantially purified mammalian protein or a portion thereof. The invention further provides isolated and purified proteins encoded by the nucleic acid molecules of SEQ ID NOs:I-I 17. Additionally, the invention provides a pharmaceutical composition comprising a substantially purified mammalian protein or a portion thereof in conjunction with a pharmaceutical carrier.
The invention further provides a method for using; at least a portion of the proteins encoded by SEQ ID NOs:I-I 17 to produce antibodies. The invention also provides a method far using a protein or a portion thereof to screen a library of molecules to identify at least one ligand which specifically binds the protein, the method comprising combining the protein with the library of molecules under conditions allowing specific binding, and detecting specific binding, thereby identifying a ligand which specifically binds the protein. Such libraries include DNA and RNA
molecules, peptides, agonists, antagonists, antibodies, immunoglobulins, drug compounds, pharmaceutical agents, and other ligands. In one aspect, the ligand identified using the method modulates the activity of the mammalian protein. In an analogous method, the protein or a portion thereof is used to purify a ligand. The method involves c;ornbining the protein or a portion thereof with a sample under conditions to allow specific binding, detecting specific binding between the protein and ligand, recovering the bound protein, and separating the protein from the iigand to obtain purified ligand.
The invention further provides a method for inserting a marker gene into the genornic DNA of an animal to disrupt the expression of the natural nucleic acid molecule. The invention also provides a method for using the nucleic acid molecule to produce an animal model system, the method comprising constructing a vector containing the nucleic acid molecule;
introducing the vector into a totipotent embryonic stem cell; selecting an embryonic stem cell with the vector integrated into genomic DNA; microinjecting the selected cell into a blastocyst, thereby forming a chirneric blastocyst; transferring the chimeric blastocyst into a pseudopregnant dam, wherein the dam gives birth to a chimeric animal containing at least one additional copy of nucleic acid molecule in its germ line; and breeding the chimeric animal to generate a homozygous animal model system.

WO 00/12?60 BRIEF DESCRIPTION OF THE SI:QUENCE LISTING
PCTIUS99/19?68 A portion of the disclosure of this patent document: contains material which is subject to copyright protection. The copyright owner has no objection to the facsimile reproduction by anyone of the patent document or the patent disclosure, as it appears in the Patent and Trademark Office patent file or records, but otherwise reserves all copyright rights whatsoever.
The Sequence Listing contains the nucleic acid sequence of exemplary nucleic acid molecules of the invention, SEQ ID NOs:l-1 I7.
MODES FOR CARRYING OUT'CHE INVENTION
Definitions "Sample" is used in its broadest sense. A sample containing nucleic acid molecules may comprise a bodily fluid; an extract from a cell, chromosome, organelle, or membrane isolated from a cell; genomic DNA, RNA, or cDNA in solution or bound to a substrate; a cell;
a biological tissue or isolated fragment thereof, for example, a needle biopsy; a fingerprint or tissue print; natural or synthetic fibres; in a solution; in a liquid suspension; in a gaseous suspension; in an aerosol; and the like.
"Plurality" refers preferably to a group of one or :more members, preferably to a group of at least about 10, and more preferably to a group of at least about 100 members, and even more preferably a group of 10,000 members.
"Substrate" refers to a rigid or semi-rigid supportt to which nucleic acid molecules or proteins are bound and includes membranes, filters, chips, slides, wafers, fibers, magnetic or nonmagnetic beads, gels, capillaries or other tubing, plates, polymers, and microparticles with a variety of surface forms including wells, trenches, pins, channels and pores.
"Modulates" refers to a change in activity {biological, chemical, or immunological) or lifespan resulting from specific binding between a maIec;ule and either a nucleic acid molecule or a protein "Microarray" refers to an ordered arrangement of hybridizable array elements on a substrate. The array elements are arranged so that there are preferably at least ten or more different array elements, more preferably at least 100 array elements, even more preferably at least 1000 array elements, and most preferably 10,000. Furthermore, the hybridization signal from each of the array elements is individually distinguishable. In a preferred embodiment, the array elements comprise nucleic acid molecules.
"Nucleic acid molecule" refers to a nucleic acidl, oligonucleotide, nucleotide, polynucleotide or any fragment thereof. It may be DNA or RNA of genomic or synthetic origin, double-stranded or single-stranded, and combined with caxbohydrate, lipids, protein or other PCTlUS99/19768 materials to perform a particular activity such as transformation or form a useful composition such as a peptide nucleic acid (PNA). "Oligonucleotide" is substantially equivalent to the terms amplimer, primer, oligomer, element, target, and probe and. is preferably single stranded.
"Protein" refers to an amino acid sequence, oligope;ptide, peptide, polypeptide or portions thereof whether naturally occurring or synthetic.
"Up-regulated" refers to a nucleic acid molecule whose levels increased in a treated sample compared with the nucleic acid molecule in an unt~~eated sample.
"Down-regulated" refers to nucleic acid molecule 'whose levels decreased in a treated sample compared with the nucleic acid molecule in an untreated sample.
"Toxic compound" or "toxic agent" is any compound; molecule, or agent that elicits a biochemical, metabolic, and physiological response in an :individual or animal, such as i) DNA
damage, ii) cell damage, iii) organ damage or cell death, car iv) clinical morbidity or mortality .
"Toxicological response" refers to a biochemical, metabolic, and physiological response in an individual, animal, or test system which has been exposed to a toxic compound or toxic agent.
"Fragment" refers to an Incyte clone or any part of a nucleic acid molecule which retains a usable, functional characteristic. Useful fragments include oligonucleotides and polynucleotides which may be used in hybridization or amplification technologies or in regulation of replication, transcription or translation. Exemplary fragments are the. first twenty consecutive nucleotides of SEQ ID NOs:I-117.
"Hybridization complex" refers to a complex between two nucleic acid molecules by virtue of the formation of hydrogen bonds between purines and pyrimidines.
"Ligand" refers to any molecule, agent, or compound which will bind specifically to a complementary site on a nucleic acid molecule or protein. Such ligands stabilize or modulate the activity of nucleic acid molecules or proteins of the invention and maybe composed of at least one of the following: inorganic and organic substances including nucleic acids, proteins, carbohydrates, fats, and lipids.
"Substantially purified" refers to nucleic acid molecules or proteins that are removed from their natural environment and are isolated or separated, .and are at least about 60% free, preferably about 75% free, and most preferably about 90% free, from other components with which they are naturally associated.
The Invention The present invention provides a composition and method of using the composition for screening test compounds and molecules for toxicological responses.
Additionally the invention provides methods for characterizing the toxicological responses of a sample to a test compound or molecule. In particular, the present invention provides a composition comprising a plurality of PCTIUS99l19768 nucleic acid molecules derived from human cDNA librarie;s, monkey cDNA
libraries, mouse cDNA libraries, normal rat liver eDNA libraries, normalized rat liver cDNA
libraries and prehybridized rat liver cDNA libraries and rat kidney cDl'iA libraries in a test system. The nucleic acid molecules have been further selected for exhibiting up-regulated or down-regulated gene expression in rat livers when the rats have been exposed to a known hepatotoxin, including a peroxisome proliferator (PP), acetaminophen or one of its. corresponding metabolites, and a polycyclic aromatic hydrocarbon (PAH).
PPs include hypolipidemic drugs, such as clofibr,ate, fenofibrate, clofenic acid, nafenopin, gemfibrozil, ciprofibrate, bezafibrate, halofenate, simfibrate, benzofibrate, etofibrate, WY-14,643, to and the like; n-alkylcarboxylic acids, such as trichloroacetic acid, valproic acid, hexanoic acid, and the like; n-alkylcarboxylic acid precursors, such as trichloroethylene, etrachloroethylene, and the like; azole antifungal compounds, such as bifenazole, and the like;
leukotriene D4 antagonists;
herbicides; pesticides; phthalate esters, such as di-[2-ethylhexylJ phthalate, mono-[2-ethylhexylJ
phthalate, and the like; and natural chemicals, such as phenyl acetate, dehydroepiandrosterone 15 sulfate, oleic acid, methanol, and the like. In a prefered embodiment the toxic compound is clofibrate, or one of its corresponding metabolites. In another prefered embodiment the toxic compound is fenofibrate, or one of its corresponding metabolites.
PAHs include compounds such as benzo(a)pyre;ne, 3-methylcholanthrene, benzo(a)anthracene, 7,12-dimethylbenz(a)anthracene, their corresponding metabolites, and the 20 like. In a preferred embodiment the toxic compound is benzo(a)pyrene, or one of its corresponding metabolites.
SEQ ID NOs: l-117 were identified by their pattern of at least two-fold up-regulation or down-regulation following hybridization with sample nucleic acid molecules from treated rat liver tissue. These and other nucleic acid molecules can be immobilized on a substrate as hybridizable 25 array elements in a microarray format. The microarra;y may be used to characterize gene expression patterns associated with novel compounds to elucidate any metabolic responses or to monitar the effects of treatments during clinical therapy where metabolic responses to toxic compounds may be expected.
When the nucleic acid molecules are employed as hybridizable array elements in a 30 microarray, the array elements are organized in an ordered fashion so that each element is present at a specified location on the substrate. Because the wray elements are at specified locations on the substrate, the hybridization patterns and intensities (which together create a unique expression profile) can be interpreted in terms of expression levels of particular genes and can be correlated with a toxicological response associated with a test compound or molecule.
35 Furthermore, the present invention provides methods for screening test compounds andlor molecules for potential toxicological responses and for screening a sample's toxicological response to a particular test compound or molecule. Briefly, these methods entail treating a sample with the test compound or molecule to elicit a change in gene expression patterns comprising the expression of a plurality of sample nucleic acid molecules.
Nucleic acid molecules are selected by identifying those levels of expressed nucleiic acid molecules in rat liver or kidney which are up-regulated or down-regulated at least 2-fold, snore preferably at least 2.5-fold, most preferably at least 3-fold, when treated with a knov~m toxic compound. The nucleic acid molecules are arrayed on a substrate. Then, the arrayed nucleic acid nnolecules and sample nucleic acid molecules are combined under conditions effective to form hybridization complexes which may be detected by methods well known in the art. Detection of higher or lower levels of such hybridization complexes compared with hybridization corr~plexes derived from samples treated with a compound that is known not to induce a toxicological response correlates with a toxicological response to a test compound or a toxicological response to a molecule.
Complementar~DNA libraries Molecules are identified that reflect all or most of the genes that are expressed in rat tissue.
Molecules may be identified by isolating clones derived from several types of rat cDNA libraries, including normal rat cDNA libraries, normalized rat cDNA, libraries and prehybridized rat cDNA
libraries. Clone inserts derived from these clones may be I>artially sequenced to generate expressed sequence tags (ESTs).
In one embodiment, two collections of ESTs are identified and sequenced. A
first collection of ESTs (the originator molecules) are derived from rat liver and kidney and from the cDNA libraries presented in the Examples. A second collection includes ESTs derived from other rat cDNA libraries available in the ZOOSEQ database (Inc;yte Pharmaceuticals, Inc., Palo Alto CA).
The two collections of ESTs are clustered electronically to form master clusters of ESTs.
Master clusters are formed by identifying overlapping EST molecules and assembling these ESTs.
A nucleic acid fragment assembly tool, such as the Phrap tool (Phil Green, University of Washington) and the GELVIEW fragment assembly system (GCG, Madison WI), can be used for this purpose. The minimum number of clones which constitute a cluster is two.
In another embodiment, a collection of human genes known to be expressed in response to toxic agents are used to select representative ESTs from the 113 rat cDNA libraries. The master cluster process is repeated for these molecules.
After assembling the clustered consensus nucleic a<;id sequences, a representative S' clone is nominated from each master cluster. The most S' clone is preferred because it is most likely to contain the complete gene. The nomination process is described in greater detail in "Relational _g_ Database and System for Storing Information Relating to Biomolecular Sequences and Reagents", USSN 09/034,807, filed March 4, 1998, herein incorporated in its entirety by reference. The EST
molecules are used as array elements on a microarray.
Selection of arraved nucleic acid molecules Samples are treated, preferably at subchronic doses, with one or more known toxic compounds over a defined time course. Preferably, the agents are peroxisomal proliferators (PPs), acetaminophen.or one of its corresponding metabolites, and polycyclic aromatic hydrocarbons (PAHs).
The gene expression patterns derived from such treated biological samples can be compared with the gene expression patterns derived from untreated biological samples to identify nucleic acid molecules whose expression is either up-regulated or down-regulated due to the response to the toxic compounds. These molecules may then be employed as array elements alone or in combination with other array element molecules. Such a microarray is particularly useful to detect and characterize gene expression patterns associated with known toxic compounds. Such 1 S gene expression patterns can then be used for comparison to identify other compounds which also elicit a metabolic response to a toxic compound.
The arrayed nucleic acid molecules can be manipulated to optimize their performance in hybridization. To optimize hybridization, the arrayed nucleic acid molecules are examined using a computer algorithm to identify portions of genes without potential secondary structure. Such computer algorithms are well known in the art and are part of OLIGO 4.06 primer analysis software (National Biosciences, Plymouth MN) or LASEF;GENE software (DNASTAR, Madison WI). These programs can search within nucleic acid molecule sequences to identify stem loop structures and tandem repeats and to analyze G + C content of the sequence (those molecules with a G + C content greater than 60% are excluded). Alternatively, the arrayed nucleic acid molecules 2S can be optimized by trial and error. Experiments can be performed to determine whether sample nucleic acid molecules and complementary arrayed nucleic acid molecules hybridize optimally under experimental conditions.
The arrayed nucleic acid molecules can be any RNfA-like or DNA-like material, such as mRNAs, cDNAs, genomic DNA, peptide nucleic acids, branched DNAs and the like.
The arrayed nucleic acid molecules can be in sense or antisense orientations.
In one embodiment, the arrayed nucleic acid molecules are cDNAs. The size of the DNA
sequence of interest may vary, and is preferably from 50 to 10,000 nucleotides, more preferably from 150 to 3,500 nucleotides. In a second embodiment, tlhe nucleic acid molecules are vector DNAs. In this case the size of the DNA sequence of interest, i.e., the insert sequence, may vary 3S from about SO to 10,000 nucleotides, more preferably from. about 1S0 to 3,500 nucleotides.

WO 0111127b0 PCT/US99/197b8 The nucleic acid molecule sequences of the Sequence Listing have been prepared by current, state-of the-art, automated methods and, as such, nnay contain occasional sequencing errors and unidentified nucleotides. Nucleotide analogues can be incorporated into the nucleic acid molecules by methods well known in the art. The only requirement is that the incorporated S nucleotide analogues must serve to base pair with sample nucleic acid molecules. For example, certain guanine nucleotides can be substituted with hypoxanthine which base pairs with cytosine residues. However, these base pairs are less stable than those between guanine and cytosine.
Alternatively, adenine nucleotides can be substituted with :?,6-diaminopurine which can form stronger base pairs than those between adenine and thymidine. Additionally, the nucleic acid molecules can include nucleotides that have been derivatizcsd chemically or enzymatically.
Typical modifications include derivatization with aryl, alk~rl, aryl or amino groups.
The nucleic acid molecules can be immobilized on a substrate via chemical bonding.
Furthermore, the molecules do not have to be directly bound to the substrate, but rather can be bound to the substrate through a linker group. The linker groups are typically about 6 to 50 atoms long to provide exposure to the bound nucleic acid molecule. Preferred linker groups include ethylene glycol oligomers, diamines, diacids and the like. Reactive groups on the substrate surface react with one of the terminal portions of the linker to bind the linker to the substrate. The other terminal portion of the linker is then functionalized for binding the nucleic acid molecule.
Preferred substrates are any suitable rigid or semirigid support, including membranes, filters, chips, slides, wafers, fibers, magnetic or nonmagnetic beads, gels, tubing, plates, polymers, microparticles and capillaries. The substrate can have a vwiety of surface forms, such as wells, trenches, pins, channels and pores, to which the arrayed nucleic acid molecules are bound.
The samples can be any sample comprising sample nucleic acid molecules and obtained from any bodily fluid (blood, urine, saliva, phlegm, gastric,juices, etc.), cultured cells, biopsies, or other tissue preparations. The samples can be derived from any species, but preferably from eukaryotic species, and more preferably from mammalian species such as rat and human.
DNA or RNA can be isolated from the sample according to any of a number of methods well known to those of skill in the art. For example, methods of purification of nucleic acids are described in Laboratory Techniques in Biochemistry and Molecular BioloaZ
Hybridization With Nucleic Acid Probes. Part I. Theory and Nucleic Acid Preparation, P. Tijssen, ed. Elsevier (1993).
In one preferred embodiment, total RNA is isolated using tl;~e TRIZOL total RNA isolation reagent (Life Technologies, Gaithersburg MD) and mRNA is isolated using oligo d(T) column chromatography or glass beads. When sample nucleic acid molecules are amplified it is desirable to amplify the sample nucleic acid molecules and maintain the relative abundances of the original sample, including low abundance transcripts. RNA can be amplified in vitro, in situ or in vivo.

WO 00/12'760 PCT/US99/19768 (See Eberwine US Patent No. 5,514,545).
It is also advantageous to include controls within i:he sample to assure that amplification and labeling procedures do not change the true distribution of nucleic acid molecules in the sample. For this purpose, a sample is spiked with an amount of control nucleic acid molecules predetermined to be detectable upon hybridization to its complementary arrayed nucleic acid molecule and the composition of nucleic acid molecules includes reference nucleic acid molecules which specifically hybridize with the control arrayed nucleic acid molecules.
After hybridization and processing, the hybridization signals obtained should reflect accurately the amounts of control arrayed nucleic acid molecules added to the sample.
Prior to hybridization, it may be desirable to fragment the sample nucleic acid molecules.
Fragmentation improves hybridization by minimizing secondary structure and cross-hybridization to other sample nucleic acid molecules in the sample or noncomplementary nucleic acid molecules. Fragmentation can be performed by mechanical or chemical means.
Labeling The sample nucleic acid molecules may be labeled with one or more labeling moieties to allow for detection of hybridized arrayed/sample nucleic acid molecule complexes. The labeling moieties can include compositions that can be detected by spectroscopic, photochemical, biochemical, bioelectronic, immunochemical, electrical, optical or chemical means. The Labeling moieties include radioisotopes, such as 32P, asp or 355, cherniluminescent compounds, labeled binding proteins, heavy metal atoms, spectroscopic markers, such as fluorescent markers and dyes, magnetic labels, linked enzymes, mass spectrometry tags, apin labels, electron transfer donors and acceptors, and the like. Preferred fluorescent markers include Cy3 and Cy5 fluorophores (Amersham Pharmacia Biotech, Piscataway NJ).
Hybridization The nulceic acid molecule sequence of SEQ ID NOs:I-117 and fragments thereof can be used in various hybridization technologies for various purposes in a test system. Hybridization probes may be designed or derived from SEQ ID NOs:I-1117. Such probes may be made from a highly specific region such as the 5' regulatory region or from a conserved motif, and used in protocols to identify naturally occurring sequences encoding the mammalian protein, allelic variants, or related sequences, and should preferably have opt least 50%
sequence identity to any of the protein sequences. The hybridization probes of the subject invention may be DNA or RNA
and may be derived from the sequence of SEQ ID NOs:l-117 or from genomic sequences including promoters, enhancers, and introns of the mammalian gene.
Hybridization or PCR probes may be produced using oligolabeling, nick translation, end-labeling, or PCR
amplification in the presence of the labeled nucleotide. A vector containing the; nucleic acid sequence may be used to produce an mRNA probe in vitro by addition of an RNA p~olymerase and labeled nucleic acid molecules. These procedures may be conducted using commercially available kits such as those provided by Arnersham Pharmacia Biotech.
The stringency of hybridization is determined by (3+C content of the probe, salt concentration, and temperature. In particular, stringency c:an be increased by reducing the concentration of salt or raising the hybridization temperature. In solutions used for some membrane based hybridizations, addition of an organic solvent such as formamide allows the reaction to occur at a lower temperature. Hybridization can be performed at low stringency with buffers, such as 5 x SSC with I% sodium dodecyl sulfate (SDS) at 60°C, which permits the formation of a hybridization complex between nucleotide ;sequences that contain some mismatches. Subsequent washes are performed at higher stringency with buffers such as 0.2 x SSC with 0.1 % SDS at either 45°C (medium stringency) or 68°C
(high stringency). At high stringency, hybridization complexes will remain stable only where the nucleic acid sequences are completely complementary. In some membrane-based hybridizations, preferably 35% or most preferably 50%, formamide can be added to the hybridization solution to reduce the temperature at which hybridization is performed, and background signals can be reduced by the use of other detergents such as Sarkosyl or Triton X-100 and a blocking; agent such as salmon sperm DNA.
Selection of components and conditions for hybridization are well known to those skilled in the art and are reviewed in AusubeI su ra) and Sambrook et al. ( 1989) Molecular Cloning. A Laboratory Manual, Cold Spring Harbor Press, Plainview NY.
Hybridization specificity can be evaluated by comparing the hybridization of specificity-control nucleic acid molecules to specificity-control sample nucleic acid molecules that are added to a sample in a known amount. The specificity-control anrayed nucleic acid molecules may have one or more sequence mismatches compared with the corresponding arrayed nucleic acid molecules. In this manner, whether only complementary arrayed nucleic acid molecules are hybridizing to the sample nucleic acid molecules or whether mismatched hybrid duplexes are forming is determined.
Hybridization reactions can be performed in absolute or differential hybridization formats.
In the absolute hybridization format, nucleic acid molecules from one sample are hybridized to the molecules in a microarray format and the signals detected after hybridization complex formation correlate to nucleic acid molecule levels in a sample. In the differential hybridization format, the differential expression of a set of genes in two biological samples is analyzed. For differential hybridization, nucleic acid molecules from both biological samples are prepared and labeled with different labeling moieties. A mixture of the two labeled nucleic acid molecules is added to a microarray. The microarray is then examined under conditions in which the emissions from the two different labels are individually detectable. Molecules in the microarray that are hybridized to substantially equal numbers of nucleic acid molecules derived from both biological samples give a distinct combined fluorescence (Shalon et al. PCT publication W095/35505). In a preferred embodiment, the labels are fluorescent markers with distinguishable excitation and emission spectra, such as Cy3 and Cy5 fluorophores.
After hybridization, the microarray is washed to remove nonhybridized nucleic acid molecules, then complex formation between the hybridizable array elements and the nucleic acid molecules is detected. Methods for detecting complex formation are well known to those skilled in the art. In a preferred embodiment, the nucleic acid molecules are labeled with a fluorescent label and measurement of levels and patterns of fluorescence indicative of complex formation is accomplished by fluorescence microscopy, preferably conjFocal fluorescence microscopy.
In a differential hybridization experiment, nucleic acid molecules from two or more different biological samples are labeled with two or more different fluorescent labels with different excitation and emission wavelengths. The labeled sample is excited with a specific excitation wavelength. Fluorescent signals are detected separately with different photomultipliers set to detect specific emission wavelengths. The relative abundances/expression levels of the nucleic acid molecules in two or more samples is obtained.
Typically, microarray fluorescence intensities can be normalized to take into account variations in hybridization intensities when more than one microarray is used under similar test conditions. In a preferred embodiment, individual arrayed-sample nucleic acid molecule complex hybridization intensities are normalized using the intensities derived from internal normalization controls contained on each microarray.
The labeled sample emits specific wavelengths which are detected using a plurality of photomultipliers. The relative abundances/expression levels of the arrayed nucleic acid molecules molecules can be used as hybridizable elements in a microarray. Such a microarray can be employed to identify expression profiles associated with pau~ticular toxicological responses. Then, a particular subset of these photomultipliers are set to detect specific wavelengths. The relative expression levels of the arrayed nucleic acid molecules can be identified as to which arrayed nucleic acid molecule expression is modulated in response to a particular toxicological agent.
These photomultipliers set to detect specific wavelengths. The relative expression levels of the nucleic acid molecules can be employed to identify other compounds with a similar toxicological response.
Alternatively, for some treatments with known side: effects, the microarray, and expression patterns derived therefrom, is employed to "fine tune" the t~~eatment regimen.
A dosage is established that minimizes expression patterns associated with undesirable side effects. This WO 00/12760 PCT/US99/19'16$
approach may be more sensitive and rapid than waiting for the patient to show toxicological side effects before altering the course of treatment.
Generally, the method for screening a library of test compounds or molecules to identify those with a toxicological response entails selecting a plurality of arrayed nucleic acid molecule genes whose expression Levels are modulated in tissues treated with known toxic compounds when compared with untreated tissues. Then a sample is treatedl with the test compound or molecule to induce a pattern of gene expression comprising the expression of a plurality of nucleic acid molecules. A test compound may be screened at several dloses to determine which doses may be toxic and which may not.
Then, the expression levels of the arrayed nucleic acid molecules and the sample nucleic acid molecules are compared to identify those compounds that induce expression levels of the sample nucleic acid molecules that are similar to those of the arrayed nucleic acid molecules. In one preferred embodiment, gene expression levels are compared by contacting the arrayed nucleic acid molecules with the sample nucleic acid molecules under conditions effective to form hybridization complexes between arrayed nucleic acid molecules and sample nucleic acid molecules, and detecting the presence or absence of the hybridization complexes.
Similarity may mean that at least 1, preferably at least 5, more preferably at least 10, ofthe upregulated arrayed nucleic acid molecules form hybridization complexes with the sample nucleic acid molecules at least once during a time course to a greater extent than would the nucleic acid molecules of a sample not treated with the test compound. Similarity may also mean that at least I, preferably at least 3, of the downregulated nucleic acid nnolecules form hybridization complexes with the nucleic acid molecules at least once during a time course to a lesser extent than would the nucleic acid molecules of a sample not treated with the test compound.
Such a similarity of expression patterns means that a toxicological response is associated with the test compound or molecule tested. Preferably, the; toxic compounds belong to the class of peroxisomal proliferators (PPs), including hypolipidemic drugs, such as clofibrate, fenofibrate, ' clofenic acid, nafenopin; gemfibrozil, ciprofibrate, bezafibrate, halafenate, simfibrate, benzofibrate, etofibrate, WY-14,643, and the Like; n-alkylcarboxylic acids, such as trichloroacetic acid, valproic acid, hexanoic acid, and the like; n-alkylcarboxylic acid precursors, such as trichloroethylene, etrachloroethylene, and the like; azole antifungal compounds, such as bifenazole, and the like; leukotriene D4 antagonists; herbicides; pesticides;
phthalate esters, such as di-[2-ethyIhexyl] phthalate, mono-[2-ethylhexyl] phthalate, and the like;
and natural chemicals, such as phenyl acetate, dehydroepiandrosterone sulfate, oleic acid, methanol, and the like. In another embodiment, the toxic compounds are acetaminopl'aen or one of its corresponding metabolites. In yet another embodiment, the toxic compound is a polycyclic aromatic hydrocarbon (PAH), including compounds such as benzo(a)pyrene; 3-m~ethylcholanthrene, benz(a)anthracene, 7,12-dimethylbenz(a)anthracene, their corresponding metalbolites, and the like. Of particular interest is the study of the metabolic responses of these cornpounds on the liver, kidney, brain, spleen, pancreas, and lung.
Modification of Gene Expression Using Nucleic Acids Gene expression may be modified by designing complementary or antisense molecules (DNA, RNA, or PNA) to the control, 5', 3', or other regulatory regions of the mammalian gene.
Oligonucleotides designed with reference to the transcription initiation site are preferred.
Similarly, inhibition can be achieved using triple helix base;-pairing, which inhibits the binding of polymerases, transcription factors, or regulatory molecules (Gee et al. In:
Huber and Carr ( 1994}
Molecular and Immunolo~ic Approaches, Futura Publishing, Mt: Kisco NY, pp. 163-177). A
complementary molecule may also be designed to block translation by preventing binding between ribosomes and mRNA. In one alternative, a library of nucleic acid molecules or fragments thereof may be screened to identify those which specifically bind a regulatory, nontransiated sequence.
Ribozymes, enzymatic RNA molecules, may also be used to catalyze the specific cleavage of RNA. The mechanism of ribozyme action involves sequence-specific hybridization of the ribozyme molecule to complementary target RNA followed by endonucleolytic cleavage at sites such as GUA, GUU, and GUC. Once such sites are identifiied, an oligonucleotide with the same sequence may be evaluated for secondary structural features which would render the oligonucleotide inoperable. The suitability of candidate targets may also be evaluated by testing their hybridization with complementary oIigonucleotides u:>ing ribonuclease protection assays.
Complementary nucleic acids and ribozymes of the: invention may be prepared via recombinant expression, in vitro or in vivo, or using solid phase phosphoramidite chemical synthesis. In addition, RNA molecules may be modified to increase intracellular stability and half life by addition of flanking sequences at the 5' and/or 3~' ends of the molecule or by the use of phosphorothioate or 2' O-methyl rather than phosphodiestemse linkages within the backbone of the molecule. Modification is inherent in the production of PNAs and can be extended to other nucleic acid molecules. The inclusion of nontraditional bases such as inosine, queosine, and wybutosine, or the modification of adenine, cytidine, guanine, thymine; and uridine with acetyl-, methyl-, thio- groups, renders the molecule less available as a substrate to endogenous endonucleases.
Screeni~ Assavs The nucleic acid molecule encoding the mammalian protein may be used to screen a library of molecules for specific binding affinity. The libraries may be DNA
molecules, RNA
molecules, PNAs, peptides, proteins such as transcription factors, enhancers, repressors, and other WO 00/12760 PCTlUS99119768 ligands which regulate the activity, replication, transcription, or translation of the nucleic acid molecule in the biological system. The assay involves combining the mammalian nucleic acid molecule or a fragment thereof with the library of molecules under conditions allowing specific binding, and detecting specific binding to identify at least one molecule which specifically binds the nucleic acid molecule.
Similarly the mammalian protein or a portion thereof may be used to screen libraries of molecules in any of a variety of screening assays. The portion of the protein employed in such screening may be free in solution, affixed to an abiotic or biotic substrate, or located intracellularly. Specific binding between the protein and molecule may be measured. Depending on the kind of library being screened, the assay may be used to identify DNA, RNA, or PNA
molecules, agonists, antagonists, antibodies, irnmunoglobulins, inhibitors, peptides, proteins, drugs, or any other ligand, which specifically binds the protein. One method for high throughput screening using very small assay volumes and very small amounts of test compound is described in USPN 5,876,946; incorporated herein by reference, which screens large numbers of molecules for enzyme inhibition or receptor binding.
Purification of Ligand The nucleic acid molecule or a fragment thereof may be used to purify a ligand from a sample. A method for using a mammalian nucleic acid molecule or a fragment thereof to purify a ligand would involve combining the nucleic acid molecule or a fragment thereof with a sample under conditions to allow specific binding, detecting specidic binding, recovering the bound protein, and using an appropriate agent to separate the nucleic acid molecule from the purified ligand.
Similarly, the protein or a portion thereof may be used to purify a ligand from a sample. A
method for using a mammalian protein or a portion thereof to purify a ligand would involve combining the protein or a portion thereof with a sample under conditions to allow specific binding, detecting specific binding between the protein andl ligand, recovering the bound protein, and using an appropriate chaotropic agent to separate the protein from the purified ligand.
PharmacoloQy Pharmaceutical compositions are those substances wherein the active ingredients are contained in an effective amount to achieve a desired and intended purpose.
The determination of an ef~'ective dose is well within the capability of those skilled in the art.
For any compound, the therapeutically effective dose may be estimated initially either in cell culture assays or in animal models. The animal model is also used to achieve a desirable concentration range and route of administration. Such information may then be used to determine useful doses and routes for administration in humans.

A therapeutically effective dose refers to that amount of protein or inhibitor which ameliorates the symptoms or condition. Therapeutic effcacy and toxicity of such agents may be determined by standard pharmaceutical procedures in cell .cultures or experimental animals, e.g., ED50 (the dose therapeutically effective in 50% of the population) and LD50 (the dose lethal to SO% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index, and it may be expressed as the ratio, LD50/ED50. ):'harmaceutical compositions which exhibit large therapeutic indexes are preferred. The data obtained from cell culture assays and animal studies are used in formulating a range of dosage for human use.
Model Systems Animal models may be used as bioassays where they exhibit a toxic response similar to that of humans and where exposure conditions are relevant to human exposures.
Mammals are the most common models, and most toxicity studies are performed on rodents such as rats or mice because of low cost, availability, and abundant reference toxicology. Inbred rodent strains provide a convenient model for investigation of the physiological consequences of under- or over-expression of genes of interest and for the development of :methods for diagnosis and treatment of diseases. A mammal inbred to over-express a particular gene, so that the protein is secreted in milk, may also serve as a convenient source of the protein expressed by that gene.
Toxicoloay Toxicology is the study of the effects of test compounds, molecules, or toxic agents on living systems to identify adverse effects. The majority of toxicity studies are performed on rats or mice to help predict whether adverse effects of agents will occur in humans.
Observation of qualitative and quantitative changes in physiology, behavior, homeostatic, developmental, and reproductive processes, and lethality are used to generate profiles of safe or toxic responses and to assess the consequences on human health following exposure to the agent.
Genetic toxicology identifies and analyzes the ability of an agent to produce damage at a cellular or subcellular level. Such genotoxic agents usually have common chemical or physical properties that facilitate interaction with nucleic acids and are most harmful when mutated chromosomes are passed along to progeny. Toxicological studies may identify agents that increase the frequency of structural or functional abnormaliities in progeny if administered to either parent before conception, to the mother during pregnancy, or to the developing organism. Mice and rats are most frequently used in these tests because of tiheir short reproductive cycle which produces the number of organisms needed to satisfy statistical requirements.
Acute toxicity tests are based on a single administration of the agent to the subject to determine the symptomology or lethality of the agent. Three experiments are conducted: 1 ) an initial dose-range-finding experiment, 2) an experiment to narrow the range of effective doses, and 3) a anal experiment for establishing the dose-response curve.
Prolonged toxicity tests are based on the repeated administration of the agent. Rat and dog are commonly used in these studies to provide data from species in different taxonomic orders.
With the exception of carcinogenesis, there is considerable evidence that daily administration ofan agent at high-dose concentrations for periods of three to four months will reveal most forms of toxicity in adult animals. Chronic toxicity tests, with a duration of a year or more, are used to demonstrate either the absence of toxicity or the carcinogenic potential of an agent. When studies are conducted on rats, a minimum of at least one tE;st group plus one control group are used. Animals are quarantined, examined for health, and monitored at the outset and at intervals throughout the experiment.
Transuenic Animal Models Transgenic rodents which overexpress or underexpress a gene of interest may be inbred and used to model human diseases or to test compound's acid molecules for therapeutic or toxicological effects. (See USPN 4,736,866; USPN 5,175,:383; and USPN
5,767,337; incorporated herein by reference). In some cases, the introduced gene rr~ay be activated at a specific time in a specific tissue type during fetal development or postnatally. Expression of the transgene is monitored by analysis of phenotype or tissue-specific mRlJA expression, in transgenic animals before, during, and after being challenged with experimental drug therapies.
Embryonic Stem Cells Embryonic stem cells (ES) isolated from rodent embryos retain the potential to form an embryo. When ES cells are placed inside a carrier embryo., they resume normal development and contribute to all tissues of the live-born animal. ES cells are the preferred cells used in the creation of experimental knockout and knockin rodent strains. Mouse ES cells, such as the mouse 129/SvJ
cell line, are derived from the early mouse embryo and are grown under culture conditions well known in the art. Vectors for knockout strains contain a disease gene candidate modified to include a marker gene which disrupts transcription andlor i:ranslation in vivo. The vector is introduced into ES cells by transformation methods such as electroporation, liposome delivery, microinjection, and the like which are well known in the art. The endogenous rodent gene is replaced by the disrupted disease gene through homologous recombination and integration during cell division. Then transformed ES cells are selected under conditions, identified, and preferably microinjected into mouse cell blastocysts such as those from the C57BL16 mouse strain. The blastocysts are surgically transferred to pseudopregnant dams and the resulting chimeric progeny are genotyped and bred to produce heterozygous or homozygous strains.
ES cells are also used to study the differentiation o~F various cell types and tissues in vitro, 35, such as neural cells, hematopoietic lineages, and cardiomyocytes (Bain et al. (1995) Dev. Biol.

168:342-357; Wiles and Keller (1991) Development 1 I 1::259-267; and Klug et al. (1996) J. Clin.
Invest. 98:216-224). Recent developments demonstrate that ES cells derived from human blastocysts may also be manipulated in vitro to differentiate into eight separate cell lineages, including endoderm, mesoderm, and ectodermal cell types {Thomson (1998) Science 282:1145-1147).
Knockout Anal~is In gene knockout analysis, a region of a human disease gene candidate is enzymatically modified to include a non-mammalian gene such as the neomycin phosphotransferase gene (neo;
Capecchi (1989) Science 244:1288-1292). The inserted coding sequence disrupts transcription and translation of the targeted gene and prevents biochemical synthesis of the disease candidate protein. The modified gene is transformed into cultured embryonic stem cells (described above), the transformed cells are injected into rodent blastulae, and the blastulae are implanted into pseudopregnant dams. Transgenic progeny are crossbred to obtain homozygous inbred lines.
Knockin Analysis Totipotent ES cells, present in the early stages of embryonic development, can be used to create knockin humanized animals {pigs) or transgenic aniimal models (mice or rats) of human diseases. With knockin technology, a region of a human gene is injected into animal ES cells, and the human sequence integrates into the animal cell genom~e by recombination.
Totipotent ES cells which contain the integrated human gene are handled as described above. Inbred animals are studied and treated to obtain information on the analogous human condition.
These methods have been used to model several human diseases. (See, e.g., Le<; et aI. (1998) Proc. Natl. Acad. Sci.
95:11371-11376; Baudoin et al. (1998) Genes Dev. 12:12()2-1216; and Zhuang et al. (1998) Mol.
Celi Biol. 18:3340-3349).
Non-Human Primate Model The field of animal testing deals with data and methodology from basic sciences such as physiology, genetics, chemistry, pharmacology and statistics. These data are paramount in evaluating the effects of test compounds or molecules on nion-human primates as they can be related to human health. Monkeys are used as human surrogates in vaccine and drug evaluations, and their responses are relevant to human exposures under similar conditions.
Cynomolgus and rhesus monkeys (Macaca fascicularis and Macaca mulatta, respectively) and common marmosets Callithrix 'aca chus) are the most common non-human primates (NHPs) used in these investigations. Since great cost is associated with developing and maintaining a colony of NHPs, early research and toxicological studies are usually carried out in rodent models. In studies using behavioral measures such as drug addiction, NHPs are the first choice test animal. In addition, NHPs and indiividual humans exhibit differential sensitivitiies to many drugs and toxins and can be _19_ WO OOII27b0 PCT/US99/19768 classified as "extensive metabolizers" and "poor metabolizers" of these agents.
In additional embodiments, the nucleic acid molecules which encode the mammalian protein may be used in any molecular biology techniques that have yet to be developed, provided the new techniques rely on properties of nucleic acid molecules that are currently known, including, but not limited to, such properties as the triplet genetic code and speciEc base pair interactions.
Examples It is understood that this invention is not limited to the particular methodology, protocols, and reagents described, as these may vary. It is also understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention which will be limited only by the appended claims.
The examples below are provided to best describe the subject invention and its representative constituents.
cDNA Library Construction The RALINOTO 1 cDNA library was constructed from liver tissue removed from a pool of fifty 10- to 11-week-old Sprague-Dawley female rats (Pharmacon, Waverly PA).
The animals were housed in standard laboratory caging and fed PMI-certifed Rodent Diet #5002. The animals appeared to be in good health at the time tissue was harvested. The animals were anesthetized by COZ inhalation, and then cardiocentesis was performed.
Frozen tissue was homogenized and lysed in TRIZOL reagent ( 1 g tissue/I0 mI
TRIZOL;
Life Technologies}, a monophasic solution of phenol and guanidine isothiocyanate, using a POLYTRON homogenizes {PT-3000; Brinkmann Instruments, Westbury NY). After a brief incubation on ice, chloroform (1:5 v/v) was mixed with the reagent, and then centrifuged at 1,000 rpm. The upper aqueous layer was removed to a fresh tube., and the RNA
precipitated with isopropanol,,resuspended in DEPC-treated water, and treated with DNase I for 25 min at 37°C.
The RNA was re-extracted once with phenol-chloroform, p:H 4.7, and precipitated using 0.3 M
sodium acetate and 2.5 volumes ethanol. The mRNA was then isolated using an OLIGOTEX kit (QIAGEN, Chatsworth CA) and used to construct the cDNA library.
The mRNA was handled according to the recommended protocols in the SUPERSCRIPT
plasmid system {Life Technologies). The cDNAs were fractionated on a SEPHAROSE

column (Amersham Pharmacia Biotech), and those cDNAs exceeding 400 by were ligated into the pINGYI plasmid vector (Incyte Pharmaceuticals). The plasmid pINCYI was subsequently transformed into DHSa or DH10B competent cells (Life Technologies).
The RAKINOTO1 library was constructed using mRNA isolated from kidney tissue removed from a pool of fifty, 7- to 8-week-old male Sprague-Dawley rats, as described above.

The RAKINOT02 library was constructed using mRNA, isolated from kidney tissue removed from a pool of fifty, 10- to 11-week-old female Sprague-Dawley rats, as described above.
II cDNA Library Normalization In some cases, cDNA libraries were normalized in a single round according to the procedure of Soares et al. (1994, Proc. Natl. Acad. Sci. 91:9228-9232) with the following modifications. The primer to template ratio inthe primer extension reaction was increased from 2:1 to 10:1. Reduction of each dNTP concentration in the reaction to 1 SO,uM
allowed the generation of longer (400-1000 nucleotide (nt)) primer extension products. The reannealing hybridization was extended from I3 to 19 hours. The single stranded DNA
circles of the normalized library were purified by hydroxyapatite chromatography, converted to partially double-stranded by random priming, and electroporated into DH1 OB competent bacteria {Life Technologies).
The Soares normalization procedure is designed to reduce the initial variation in individual cDNA frequencies and to achieve abundances within one order of magnitude while maintaining the overall sequence complexity ofthe library. In the normalization process, the prevalence of high-abundance cDNA clones decreases significantly, clones with mid-level abundance are relatively unaffected, and clones for rare transcripts are in<;reased in abundance. In the modified Soares normalization procedure, significantly longer hybridization times axe used to increase gene discovery rates by biasing the normalized libraries toward low-abundance cDNAs that are well represented in a standard transcript image.
The RALINON03; RALINON04, and RALINON(17 normalized rat liver cDNA libraries were constructed with 2.0 x 106, 4.6 x 105, and 2.0 x 1 O6 independent clones from the RALINOTO1 cDNA library, respectively. The RALINOT01 cDNA library was normalized in one round using conditions adapted from Soares su ra) except that a signii:icantly longer (48-hour) reannealing hybridization was used.
III cDNA Library Prehybridization The RALINOHO 1 cDNA library was constructed with clones from the RALINOTO 1 cDNA library. After preparation of the RALINOTO1 cDN.A library, 9,984 clones were spotted onto a nylon filter, lysed, and the plasmid DNA was bound to the filter. The filter was incubated with pre-warmed hybridization buffer and then hybridized at 42°C for 14-16 hours in 0.75 M
NaCI, 0.1 M Na2HP0,/NaH2P04, O.IS M tris-HCI (pH 7.5), Sx Denhardt's Solution, 2% SDS, 100 p.g/ml sheared salmon sperm DNA, SO% formamide, and [~s2P]-labeled oligonucleotide molecules made from reverse transcribed rat liver mRNA from an untreated animal. The filter was rinsed with 2 x SSC (saline sodium citrate) at ambient temperature for S minutes followed by washing for 30 minutes at b8°C with pre-warmed washing solution (2 x. SSC, I% SDS).
The wash was repeated with fresh washing solution for an additional 30 nninutes at 68°C. Filters were then washed twice with pre-warmed washing solution (0.6 x SSC, 1% SDS) for 30 minutes at 68°C.
Some 4,224 clones had very low hybridization signals and about 2U% of the clones had no signals and two groups were isolated and sequenced.
IV Isolation and Sequencing of cDNA Clones DNA was isolated using the following protocol. Single bacterial colonies were transferred into individual wells of 384-well plates (Genetix Ltd, Christchurch, United Kingdom) using sterile toothpicks. The wells contained 1 ml of sterile Terrific Broth (Life Technologies) with 25 mg/1 carbenicillin and 0.4% glycerol (v/v). The.plates were covered and placed in an incubator (Thermodyne, Newtown Square PA} at 37°C for 8-10 hours. Plasmid DNA was released from the cells and amplified using direct link PCR (Rao, V.B. (1994!.) Anal. Biochem.
216:1-14) as follows.
The direct link PCR solution included 30 ml ofNUCLEIX PLUS PCR nucleotide mix (Amersham Pharmacia Biotech, Piscataway NJ) and 300 pl of Taq DN.A polymerase (Amersharn Pharmacia Biotech). Five microlitres of the PCR solution were added to each of the 384 wells using the MICROLAB 2200 system (Hamilton, Reno NV); plates ware centrifuged at 1000 rpm for 20 seconds and refrigerated until use. A 384 pin tool (V&P Scientific Inc, San Diego CA) was used to transfer bacterial cells from the incubation plate into the plate containing the PCR solution where 0.1% Tween 20 caused the cells to undergo lysis and release the plasmid DNA. After lysis, the plates were centrifuged up to 500 rpm, covered with a cycle sealer, and cycled using a 384-well DNA ENGINE thermal cycler (MJ Research, Watertown MA) using the program dPCR30 with the following parameters: Step I) 95°C, 1 minute; Step 2) 94°C, 30 seconds; Step 3) 55°C, seconds; Step 4) 72°C, 2 minutes; Step 5) steps 2, 3, and 4 repeated 29 times; Step 6) 72°C, 10 minutes; and Step 7) storage at 4°C.
The concentration of DNA in each well was deterniined by dispensing 100 pl PICO
25 GREEN quantitation reagent (0.25% (v/v), Molecular Probes, Eugene OR) dissolved in lx TE and 0.5 pl of undiluted PCR product into each well of an opaque fluorirneter plate (Corning Costar, Acton MA), allowing the DNA to bind to the quantitation reagent. The plate was scanned in a Fluoroscan II (Labsystems Oy, Helsinki, Finland} to measure the fluorescence of the sample and to quantitate the concentration of DNA. Typical concentrations of each DNA sample were in the 30 range of 100 to 500 ng/ml.
The cDNAs were prepared for sequencing using eii:her a HYDRA microdispenser (Robbins Scientific, Sunnyvale CA) or MICROLAB 2200 system (Hamilton) in combination with the DNA ENGINE thermal cyclers (MJ Research). The cD~NAs were sequenced using 'the method of Sanger, F. and A.R. Coulson (J. Mol. Biol. (1975) 94:441-448) and the ABI
377 sequencing systems (PE Biosystems). Most of the isolates were sequenced according to standard ABI

protocols using ABI kits (PE Biosystems). The solution volumes were used at 0.25x - 1.Ox concentrations. Typically, 500 to 700 base pairs were sequenced in 3.5 to 4 hours. In the alternative, cDNAs may have been sequenced using solutions and dyes from Amersham Pharmacia Biotech.
V Rat Liver and Kidney Gene Selection As a first step, originator molecules from high throughput sequencing experiments were derived from clone inserts from RALINOT01, RAKINOT01, RAKINOT02, RALINOHO1, RALTNON03, RALINON04 and RALINON07. cDNA library clones were obtained. There were 18,140 rat liver molecules and 5,779 rat kidney molecules.
i0 Additionally, 1,500 rat molecules derived from cleme inserts of any of 113 rat cDNA
libraries were selected based on their homology to genes coding for polypeptides implicated in toxicological responses including peroxisome-associated genes, lysosome-associated genes, apoptosis-associated genes, P450 cytochromes, detoxification genes such as sulfotransferases, glutathione S-transferase, and cysteine proteases, and the liike.
15 Then, all the remaining molecules derived from all of the rat cDNA library clones were clustered based on the originator molecules described above. The clustering process involved identifying overlapping molecules that have a match quality indicated by a product score of 50 using BLAST.
6581 master clusters were identified.
20 After forming the clone clusters, a consensus sequence was generated based on the assembly of the clone molecules using Phrap (Phil Green, l;lniversity of Washington). The assembled molecules were then annotated by first screening the assembled molecules against GenBank using BLASTn and then by screening the assembled molecules against GenPept using FASTX. About two thirds of the assembled molecules were annotated, about one third of the 25 assembled molecules were not annotated.
VI Substrate and Array Etement/Probe Preparation Clones nominated in the process described in Example V were used to generate array elements. Each array element was amplified from bacterial cells. PCR
amplification used primers complementary to the vector sequences flanking the cDNA insert. Array elements were amplified 30 in thirty cycles of PCR from an initial quantity of 1-2 ng to a final quantity greater than 5 p,g.
Amplified array elements were then purified using SEPHACRYL-400 (Amersham Phar~rnacia Biotech).
Purified array elements were immobilized on polynner-coated glass slides.
Glass microscope slides (Corning, Corning NY) cleaned by ultrasound in 0.1% SDS and acetone; with 35 extensive distilled water washes between and after treatments. Glass slides were etched in 4%

WO 00/127b0 PCTIUS99119768 hydrofluoric acid (VWR, West Chester PA), washed extensively in distilled water, and coated with 0.05% aminopropyl silane (Sigma-Aldrich, St. Louis MO) in 95% ethanol. Coated slides were cured in a 110 °C oven.
Array elements were applied to the coated glass substrate using a procedure described in US Patent No. 5,807,522 and incorporated herein by reference. In brief, 1 pl of the array element DNA, at an average concentration of 0.5 pglml in 3 x SSC, was loaded into the open capillary printing element by a high-speed robotic apparatus. The apparatus then deposited about 5 nl of the array element sample per slide. A total of 7404 array elements representing rat liver and kidney genes and a variety of control elements, including 14 synthetic control molecules, human genomic DNA, and yeast genomic DNA, were arrayed in four identical quadrants within a 1.8 cmz area of the glass substrate.
Microarrays were UV-crosslinked using a STRAT.ALINKER UV-crosslinker (Stratagene). Microarrays were washed at room temperature once in 0.2% SDS and three times in distilled water. Non-specific binding sites were blocked b~~ incubation of microarrays in 0.2%
t5 casein in phosphate buffered saline (PBS) {Tropix Inc., Bedford MA) for 30 minutes at 60°C
followed by washes in 0.2% SDS and distilled water as before.
VII Target Preparation Male Sprague-Dawley rats (6-8 wk old) were dosed intraperitoneaily with clofibrate (CLO; Acros, Geel, Belgium) at 250 mg/kg body weight lbw), acetaminophen (APAP; Acros) at 1000 mg/kg bw, benzo(a)pyrene (B(a)P; Acros) at I O mg/k.g bw, or dimethylsulfoxide vehicle (DMSO; Acros) at less than 2 mllkg bw and the animals were later euthanized by COz inhalation.
Animals were monitored daily for physical condition and body weight. Three animals per group were sacrificed approximately 12 hours, 1 day (d), 3d, 7d, :14d, and 28d following the single dose.
Prior to sacrifice a blood sample from each animal was drawn and assayed for serum alanine transferase (ALT) and aspartate aminotransferase (AST) levels using a diagnostic kit {Sigma-Aldrich). Observed gross pathology and liver weights wer<; recorded at time of necropsy. Liver, kidney, brain, spleen and pancreas from each rat were harvested, flash frozen in liquid nitrogen, and stared at -80°C.
Far each probe preparation, frozen liver was homogenized and lysed in TRIZOL
reagent (Life Technologies, Gaithersburg MD) following the modifications for liver RNA
isolation.
Messenger RNA was isolated using an OLIGOTEX kit (QLAGEN) and labeled with either Cy3- or Cy5-labeled primers (Operon Technologies, Alameda CA) using the GEMBRIGHT
labeling kit (Incyte Pharmaceuticals). Messenger RNA isolated from tissues of rats treated with clofibrate, acetaminophen, or benzo(a)pyrene was labeled with Cy5 and mRNA isolated from tissues of rats treated with DMSO was labeled with Cy3. Quantitative an~i differential expression pattern control WO 00/12760 PCTlUS99/19768 cDNAs were added to each labeling reaction. Labeled cDNA was treated with 0.5 M sodium bicarbonate (pH 9.2) for 20 min at 85 °C to degrade the RNA and purified using two successive CHROMA SPIN 30 gel filtration spin columns (Clontech, Palo Alto CA). Cy3-labeled control sample and Cy5-labeled experimental sample were combined and precipitated in glycogen, sodium acetate, and ethanol.
Probes are also prepared from tissue needle biopsy samples. Samples are used to identify changes within the tissue following exposure to, for example, a toxic compond, a potential toxic compound, a compound with unknown metabolic responses, or a pharmacological compound.
VIII Hybridization Hybridizations were carried out using the methods described by Shalon su ra).
IX Detection The microscope used to detect the reporter-labeled hybridization complexes was equipped with an Innova 70 mixed gas 10 W laser (Coherent Lasers; Santa Clara CA) capable of generating spectral lines at 488 nm for excitation of Cy3, and 632 nm fox excitation of CyS. The excitation laser light was focused on the array using a 20x microscope objective (Nikon, Melville NY}. The slide containing the array was placed on a computer-controlled X-Y stage on the microscope and raster-scanned past the objective. The 1.8 cm x 1.8 cm array used in the present example was scanned with a resolution of 20 micrometers.
In two separate scans, a mixed gas multiline laser excited the two fluorophores sequentially. Emitted light was split, based on wavelength, into two photomultiplier tube detectors (PMT 81477, Hamamatsu Photonics, San Jose CA) corresponding to the two fluorophores.
Appropriate filters positioned between the array and the photomultiplier tubes were used to filter the signals. The emission maxima of the fluorophores used were S65 nm for Cy3 and b50 nm for CyS. Each array was typically scanned twice, one scan per fluorophore using the appropriate filters at the laser source, although the apparatus was capat>le of recording the spectra from both fluorophores simultaneously.
The sensitivity of the scans was typically calibrated using the signal intensity generated by a cDNA control species added to the probe mix at a known concentration. A
specific location on the array contained a complementary DNA sequence, allovving the intensity of the signal at that location to be correlated with a weight ratio of hybridizing species of 1:100,000. When two probes from different sources (e.g., representing test and control cells), each labeled with a different fluorophore, are hybridized to a single array for the purpose of identifying genes that are differentially expressed, the calibration was done by labeling samples of the calibrating cDNA
with the two fluorophores and adding identical amounts of each to the hybridization mixture.
The output of the photornultiplier tube was.digitize;d using a I2-bit RTI-835H
analog-to-digital (AID) conversion board (Analog Devices, Norwood AqA) installed in an IBM-compatible PC computer. The digitized data were displayed as an image. where the signal intensity was mapped using a linear 20-color transformation to a pseudocolor scale ranging from blue (low signal) to red (high signal). The data was also analyzed quantitatively. Where two different fluorophores were excited and measured simultaneously, the data were first corrected for optical crosstalk (due to overlapping emission spectra) between the ifluorophores using each fluorophore's emission spectrum.
A grid was superimposed over the fluorescence signal image such that the signal from each spot was centered in each element of the grid. The fluorescence signal within each element was then integrated to obtain a numerical value corresponding to the average intensity of the signal. The software used for signal analysis was the GEMT'OOLS gene expression analysis program (Incyte Pharmaceuticals). In one analysis, where two different samples were prepared from identically treated cell cultures, expression patterns of those cDNAs which changed between 1.6- and 1.7-fold were within the 95% confidence limits of a Poisson normal distribution profile (T. Theriault, pers. communication).
X Results The expression patterns of eight cytochrame P450 isozymes known to be induced in a toxicological response were monitored during the 28 day time course. The results using clofibrate, acetaminophen, and benzo(a)pyrene are shown in Table 1, Table 2, and Table 3, respectively.
Each of the known genes was upregulated greater than 2 foldl at least once during the time course.
TABLE 1 Gene expression patterns (x fold increase) of known genes in clofibrate-treated rat liver Gene 12 hours 1 day 3 days'. 7 days 28 days P450 LA- 15 26 2.0 2.1 3.0 omega P450 4A 6.5 16.5 2.1 3.0 3.5 P450 3A 0.14 1.6 0.63 0.50 0.45 TABLE 2 Gene expression patterns (x fold increase) of known genes in acetaminophen-treated rat liver Gene 12 hours 24 hours 3 days 7 days 14 days 28 days P450A 1 4:4 2.2 2.0 4.6 4.8 P450F 0.50 0.23 2.0 1.8 2.2 2.2 P45014DM 0.45 0.32 2.2 1.6 1.8 0.56 WO 00/12760 PCT/US99/19'168 TABLE 3 Gene expression patterns (x fold increase) of knowmgenes in benzo(a)pyrene-treated rat liver Gene 12 hours1 day 3 days 7 days 14 days 28 days P450 LA-omega 1.2 2.3 2.4 1.4 6.8 1.2 P450 MCA-inducible8.2 11.8 4.4 2.2 2.4 1.2 P450ISFB-NF 9.6 7.4. 6.2 2.4 2.4 1.2 We have discovered novel nucleotide molecules that are up-regulated or down-regulated at least 2-fold at least once during the time course. These molecules are SEQ ID
NOs: l-117 provided in the Sequence Listing. These polynucleotide molecules can be used for screening test compounds or molecules for a toxicologic effect.
Table 4 shows the gene expression pattern of selected molecules that were upregulated at least 2-fold at least once during the time course following treatment with clofibrate (CLO) and Table 5 shows the gene expression pattern of selected molf;cules that were downregulated at least 2-fold at least once during the time course following treatment with clofibrate.
TABLE 4 Gene expression patterns (x fold increase) of CLO-upregulated nucleic acid moleucles SEQ ID 12 hours 1 day 3 days 7 days 28 days NO:

35 11.6 14.4 2.4 3.0 3.2 36 11.6 18.7 3.0 3.3 3:8 31 i .2 2.8 1.() 2.3 4.8 57 0.9 1.9 O.S> 1.5 4.5 67 4.3 1.1 l .fi 1.7 5.7 81 5.1 1.2 1. ;~ 1.8 6.0 94 4.8 1.4 2.0 1.5 2.4 33 5.1 1.3 1.S) 1:8 5.5 TABLE 5 Gene expression patterns (x fold increase) o~FCLO-downregulated nucleic acid molecules SEQ ID 12 hours 1 day 3 days 7 days 28 days NO:

102 0.15 i.4 1.0 0.77 0.67 103 0.13 1.2 0.83 0.63 0.56 52 O.I3 . 0.56 0.37 1.0 1.2 43 0.13 1.1 0.91 0.71 0.56 53 0.11 0.67 0.36 1.0 1.2 54 0:14 0.63 0.59 1. i 0.29 55 0.16 0.67 0.71 1.2 0.32 63 0.33 0.14 1.1 0.83 1.2 105 0.14 1.2 1.0 0.77 0.7 i 68 0.16 0.67 0.53 1.1 1.4 71 0.43 0.18 0.40 0.34 0.23 74 0.06 0.71 0.42 1. i 1.2 115 0.22 1.5 0.77 i.7 1.3 8S 0.19 0.45 1.0 1.3 1.8 90 0.12 0.48 1.2 1.0 1.2 95 0.14 0.91 0.56 1.5 1.4 Table 6 shows the gene expression pattern of selected molecules that were upregulated at least 2-fold at least once during the time course following treatment with acetaminophen (APAP) and Table 7 shows the gene expression pattern of selected molecules that were downregulated at Least 2-fold at least once during the time course following treatment with acetaminophen.

-2g- .

TABLE 6 Gene expression patterns (x fold increase) of AF'AP.-upregulated nucleic acid molecules SEQ ID NO: 12 hours24 hours 3 days 7 days 14 days 28 days 35 3.1 6.6 2.9 3.3 4.9 7.5 36 4.7 10.1 4.0 4.2 6.9 9:8 78 0.9 4:4 1.2 I.S 1.1 1.4 81 2.9 5.1 1.4 1.8 2.3 2.4 82 1.2 4.2 i.3 1.0 1.7 1.4 39 2.4 9.0 2.6 1.7 2.2 2.4 94 1.2 4.9 1.2 1.I 2:0 2.0 33 4.3 5.9 1.5 1.7 2.9 3.2 98 1.3 6.1 1..5 1.9 1.8 2.f TABLE 7 Gene expression patterns (x fold increase) o:f APAP-downregulated nucleic acid molecules SEQ ID 12 hours1 day 3 days 7 days 14 days 28 days NO:

49 0.59 0.15 1.2 1.0 0.83 1.1 50 0.83 0.37 0.43 0.37 0.22 0.2 52 0.63 0.08 1.0 0.71 0.83- 0.45 53 0.25 0.07 1.1 0.71 0.83 0.42 54 0.43 O. I9 0.04 0.71 0.29 0.36 55 0.35 0.22 0.07 0.77 0.31 0.42 56 0.38 0.21 0.5 0.32 1.1 1.1 59 0.18 0.77 2.5 1.4 1.2 1.6 61 0.15 0.53 0.91 0.71 0.71 I.8 63 0.13 0.05 0.23 0.77 0.43 0.77 74 0.19 0.09 1.I 1.0 1.4 0.56 87 0.42 O.IO 0.53 0.63 0.63 0.67 90 0.16 0.29 1.2 0.77 0.83 1.1 95 0.22 0.20 2.7 1.7 I.6 1.0 Table 8 shows the gene expression pattern of selected molecules that were upregulated at least 2-fold at least once during the time course following tz~eatment with benzo(a)pyrene (B(a)P) and Table 9 shows the gene expression pattern of selected nnolecules that were downregulated at least 2-fold at least once during the time course following treatment with benzo(a)pyrene.
TABLE 8 Gene expression patterns of B(a)P-upre;guiated nucleic acid molecules SEQ ID 12 hoursi day 3 days 7 days 14 days 28 days NO:

3 3.4 1.9 0.7 0.S 1.99 0.77 9 1.6 3.2 1.2 1.1 3 1.S

10 2.8 S.9 3.2 2.1 2.9 1.8 13 2.9 6.1 3.1 2.3 3.3 1.9 19 2.7 3.S 3 1.9 1.7 1.S

26 1.1 4.7 1.S 1.3 S 2 1S 31 2.3 3.8 1.6 2 1.7 2.I

3 3 2.1 4.1 3.2 2 1.7 1.6 3 5 1.2 3 5.1 1.4 S 1.3 3 7 3.4 0.S 0.6 0.7 0.9 O.S

39 1.S 3.S 1.8 1.S 3.S 2.1 42 9.1 9.1 S.2 2.4 2.1 1 TABLE 9 Gene expression patterns of B(a)P-downregulated nulciec acid molecules SEQ ID 12 hours1 day 3 days 7 days 14 days 28 days NO:

2S i I 0.3 O.S 0.4 0.3 O.S3 O.S3 2S 0.3 0.9 O.S 0.7 0.42 2.1 27 1 0.1 1 1.1 0.09 O.S3 28 0.3 0.3 1.2 ~ 1.2 0.77 1.1 4S 1.2 0.2 0.4 0.6 0.77 0.37 SEQUENCE LISTING
<110> INCYTE PHARMACEUTICALS, INC.
CUNNINGHAM, Mary Jane ZWEIGER, Gary B.
PANZER, Scott R.
SEILHAMER, Jeffrey J.
<120> TOXICOLOGICAL RESPONSE MARKERS
<130> PA-0010 PCT
<140> To Be Assigned <141> Herewith <150> 09/141,825; 09/172,711; 09/172,108 <151> 1998-08-28; 1998-10-13; 1998-10-13 <160> 117 <170> PERL Program <210> 1 <211> 259 <212> DNA
<213> Rattus norvegicus <220>
<221> misc_feature <223> Incyte template ID No: 700416862F7 <400> 1 gtggcggcga tttctgcgtc gagcatttgg agtttcttcg ct<~ctgaacg ggtagactaa 60 acggcggctg acatggtgga ggaggtacag aagcattctg tgcacacact agtgttcagg 120 tcattgaaga ggacccatga catgtttgtg gctgataatg gaaaacctgt gcctttggat 180 gaagagagtc acaagcggaa aatggcaatc aagcttcgta at<~agtatgg ccctgtgctg 240 catatgccta cttcaaaag 259 <210> 2 <211> 295 <212> DNA
<213> Rattus norvegicus <220>
<221> unsure <222> 212 , 227, 229, 232, 240, 243, 245, 250, :?57, 267, 269, 273, 277 <222> 288, 290 <223> a or g or c or t, unknown, or other <220>
<221> misc_feature <223> Incyte template ID No: 700502957F6 <400> 2 gcctcttcca ccatccggcc tagtcactgc aggggccatg cct:acctatt ccactcaact 60 tgttacctct gcggctccag gcagggctta gtccaacctg cccagacacg gttcaccttt 120 ttatgcccaa gctttcgggg tgctgaggta ggggctgcct t~cctgcaccc ccaaggagca 180 gacactcaag aatggagtca gctaggaacc cngggagctg cctcatnang cncttgatan 240 cangnacacn tttgcanctg cagaccntnt tcngaanaac wttgccangn tcaac 295 <210> 3 <211> 273 <212> DNA
<213> Rattus norvegicus <220>
<221> unsure <222> 56, 220, 235, 237, 239, 249, 256 <223> a or g or c or t, unknown, or other <220>
<221> misc_feature <223> Incyte template ID No: 700504502F6 <400> 3 tgaccctgct tgctgcaggt gactggtcaa gtgcgagcta gcatagttag tgtggngtat 60 aaggcgccat cattcctcca gtaagcctcc atcccaaagc aactgaggct gtggcagtga 120 tgccagcaac ctgtgtcacc caaaattatc cagccctcca cc~ggcactgc ctaggacctg 180 gggagggaag ggactttgca tcacatagcc tcaggttcgn gtatggctct ggtangngnt 240 gcctgaaant ggtggnttcc agctggtgta cgg 273 <210> 4 <211> 264 <212> DNA
<213> Rattus norvegicus <220>
<221> misc_feature <223> Incyte template ID No: 700505170F6 <400> 4 ggctggtctg cgatggcccg ctacctcggc tcgctggaac ca.tgtgtggg tccggcactt 60 gagactggaa tcctgaaagg ggtgaacctt cagcggaaac ttgcggcaaa ttttactccg 120 tccggacagc cacggcggga ggaggcagtg aatgctttgt gctggggcac aggcggcgag 180 acccagattt tggtgggatg tgcggacagg accgtgaggc actttaatgc ggaggagggt 240 acattccaga ccagagatac tgcc 264 <210> 5 <211> 268 <212> DNA
<213> Rattus norvegicus <220>
<221> unsure <222> 231 <223> a or g ox c or t, unknown, or other <220>
<221> misc feature WO 00!12760 PCT/US99/19768 <223> Incyte template ID No: 700511170F6 <400> 5 ggcaacaaga cgctgtgatt ggaagcaatg acgaagtcct cacactccgg ggagtgggta 60 tgtgctgcta catcatgtga tgggcagcct ggaggggatg cagggcgcct ggagctatgt 120 ccagggtggc atgggtgccc tctcagatgc cattgcaagc tcggctactg cacatggagc 180 aagtatcttc acagagaaga ctgtggctaa ggtgcaagtg aacagcgaag ncgtgtccaa 240 ggggtcgtgc tcagggccgg cgaggagt <210> 6 <211> 284 _ <212> DNA
<213> Rattus norvegicus <220>
<221> unsure <222> 28, 37, 44, 67, 71, 88, 102, 172, 238 <223> a or g or c or t, unknown, or other <220>
<221> misc_feature <223> Incyte template ID No: 700607827F7 <400> 6 gtgtacctac ctgctgagga aggaaggngt ggatggnacc cagnaacctg atgtccagca 60 caagggnaac nggcgtggct ttctaatnta caagcctggg tnactacagc ttgcagctac 120 ctaacccatg caggaggcga accctctgag cccagttgct atagtgacca tnaagatgtc 180 ttgccacaca gcttccaccc agtctgggtt taatgggaag tt:acctaacg attacccnca 240 gaagacacat gagacgcttg cttcaaagct ctcggatgca gc:ca 284 <210> 7 <211> 243 <212> DNA
<213> Rattus norvegicus <220>
<221> misc_feature <223> Incyte template ID No: 700500814F6 <400> 7 actttttcta atgtcttatg gccacttctt atgagaatgg ggagctgctc tgcctgaggg 60 tcgtgagagg aagcgccaga gcaggcccat catcccaacc cttggccttg gcccttcccc 120 ctagctctgc agcatttctt cagatcctct ttcctgagag tcaaggagac taaacaccaa 180 taaaccagac acaaccttcg tggccccaaa ggagaaaccg attagagggt tctctgctag 240 atg 243 <210> 8 <211> 259 <212> DNA
<213> Rattus norvegicus <220>
<221> unsure <222> 235 WO 00/I2760 PCTIUS99/19'168 <223> a or g or c or t, unknown, or other <220>
<221> misc_feature <223> Incyte template ID No: 700526819F6 <400> 8 ggcgcaggcg gaaggggcct gtcaccgtcc gctgcgacgt cgcggctgga gttgaacctg 60 gtgccggctg ctttgcgctg tgagtcgatg gcggccgaaa aacgagaacc ggacgagtgg 120 cgtctggaga agtatgtggg tccc~ggaag acatgctgca g~ccctgaaag tccaagcaag 180 taaaccgcct cggaagtgat cagtgagtac tcccgcaaag tgactttctg aaggnatgct 240 gaggctgaga agtgactct 259 <210> 9 <211> 255 <212> DNA
<213> Rattus norvegicus <220>
<221> unsure <222> 2, 4, 53, 55 ,86, 88, 92, 106, 233, 211" 214 <223> a or g or c or t, unknown, or other <220>
<221> misc_feature <223> Incyte template ID No: 7005281?6F6 <400> 9 cnanggccct cagggaatca agaggagcca gcctgatccc tc~gcctctgg agncntaaaa 60 caagtgtgtt tttgcaggta gcctangntg gntgtcgatg gagctncagc ctgcatggca 120 ttaggcagga agncactctg gatgattgtg cacatgagaa ccaagtcagg gagggagggt 180 ttaaggagag gcttagaata caagtgagaa ncancgagaa ac~ggaccaag tcctcagaat 240 agaagctatc tgcct 255 <210>ZO

<211>269 <212>DNA

<213>Rattus norvegicus <220>
<221> unsure <222> 30-31, 140 <223> a or g or c or t, unknown, or other <220>
<221> misc_feature <223> Incyte template ID No: 700528082F6 <400> 10 ataaaagtga aaactgggca agggcaaggn ngctgggcgt gaaccgctta ctagataatg 60 gtctctaaaa attggctctg aaaaccctgt ttgtgtattc gttttatgag tgcttaaaaa 120 tggtgtgacc agggcatggn cactgtcatt ggaacagcaa catgcttgct ggcacattgg 180 aatggggaaa tgtgaagaaa gctggcatca ggcctgcggc acccatttct ttgatgaaag 240 tgttgtgtca aacccccact aatcatttt 269 <210> 11 <211> 254 <212> DNA
<213> Rattus norvegicus <220>
<221> unsure <222> 36, 47, 67, 80, 82-83, 92 , 111 <223> a or g or c or t, unknown, or other <220>
<221> misc_feature <223> Incyte template ID No: 700535328F6 <400> 11 caaggcgttc tgctgcgaga acgacattga catcgngcgc gt:ggtanacg tgcggaggct 60 ggcggcnatc gtgggcgccn annacgagag gngcgcgccg t<~agacttgc nttgcatcct 120 catttcgaac cctaatgaag acacatggaa ggaccctgcc tt:ggagaagc tcagtttgtt 180 ctgcgaggag agccgcagct tcaacgactg ggtcccagca tc:acccttcc gagtgacagc 240 ctgcagggac cttg <210> 12 <211> 244 <212> DNA
<213> Rattus norvegicus <220>
<221> unsure <222> 50, 102, 169, 171, 204, 210, 234, 242 <223> a or g or c or t, unknown, or other <220>
<221> misc feature <223> Incyte template ID No: 700368973F6 <400> 12 cacaatccca aactggaaaa acttaaaaag gaatcctgct gt.gaaaggtn tatattactc 60 tagatttttc ttactgtaaa tattgtaaga ttgtaatact gn.caatattt tattaaccaa 120 caaatgttaa tctatgtgaa atcagactta tttaaagggc tg~ctattang ngtgtggccc 180 tttgctgaca gattaagtat attntgagtn agataactta ttaaggatgg aacnttaaag 240 gntc 244 <210> 13 <211> 237 <212> DNA
<213> Rattus norvegicus <220>
<221> unsure <222> 11, 20, 132, 136, 149, 151, 158, 171, 173, 184, 187, 190, 193 <222> 204-205, 208, 212-213, 215, 221, 227, 230-231, 236 <223> a or g or c or t, unknown, or other <220>
<221> misc feature <223> Incyte template ID No: 700368974F6 <400> 13 gtccttagct ngtgggcggn ggggtgcagt ctgctactat ctgaacgaat ttaatgtggg 60 agcatgcctt atacaacaca ggaaattaat gtgtgatcta atgcgtgatc tatgacttat 120 tacaatacag anttangtgt gaacctgcnt ncaaaacngg tcagaatttt ngnaatggcc 180 ggantgnacn ggntgnttat taanntgnaa gnngntggga naggccnggn ntgcgnt 237 <210> 14 <211> 235 <212> DNA
<213> Rattus norvegicus <220>
<221> unsure <222> 38, 49, 53, 55, 107, 125, 132, 136, 138, 150-151, 163, 165-166 <222> 179-180, 184, 186, 189, 192, 199, 219-2:21, 223 <223> a or g or c or t, unknown, or other <220>
<221> misc_feature <223> Incyte template ID No: 700369461F6 <400> 14 ctttaaccgg tgggctgctg taagaatcgg tggcaggnct ci:.ctctgcng ggngntaatt 60 gctctggaac gctactagga cccgaatact aaggccacat ci~ctacngtc taagagggga 120 aatangatag cnttgntncc acatgtggcn nagtggggtt gcngnntatn gcttaacann 180 tacnanttnc antgattant gtggtggtaa gatggcttnn ni~naaaactg ccgcc 235 <210> 15 <211> 205 <212> DNA
<213> Rattus norvegicus <220>
<221> unsure <222> 17, 19, 21, 56, 69, 75, 81, 103, 109, 1T.1, 122, 127, 130, 137 <222> 148, 151, 153, 166, 174, 177, 190, 193, 195 <223> a or g or c or t, unknown, or other <220>
<221> misc_feature <223> Incyte template ID No: 700782579F6 <400> 15 gggtcattta caacctntna nacaagggga cgcccccaga ca.tgccagtg ttcacngaac 60 aagatgcang tccancagga ncagatagac tcagtccatg ga.ntggctna ncaaccagcc 120 cngggcngcn caactgntgg acangtangg nantttctgc ga.caantggt gagnttnttg 180 cgaagctccn tgncngaaag aatgg 205 <210> 16 <211> 236 <212> DNA
<213> Rattus norvegicus <220>
<221> unsure <222> 11-12, 33-34, 46, 76, 85-86, 103, 123, 127, 144, 152, 157, 162 <222> 169, 174, 183-184, 186, 191-194, 217 ,224, 230 <223> a or g or c or t, unknown, or other <220>
<221> misc_feature <223> Incyte template ID No: 700782665F6 <400> 16 ggtctccatg nngaccgggc gccttggggt tgnngagacg ctgcangccc ttaacgcccg 60 cttgtagggc ccttgnaacc ccggnntggt ttaaggaaaa cgnatgcccg acaccttcgt 120 gtncganact ttttggcacc gcgnaaactc gnttacngtg gnttttnang tagngggtat 180 gtnncncgag nnnntttagg ccggcttgtg ctgcggnatt gggntgaaan tgtctg 236 <210> 17 <211> 267 <212> DNA
<213> Rattus norvegicus <220>
<221> misc_feature <223> Incyte template ID No: 700480927F6 <400> 17 ctggaccaac atcacaagaa atgaataaag cagatttctc tgttgagttc tgcagtaaac 60 cacctaaaag ccaatgtcaa gtcagccgca gacttactta gcctgcctag cactgtagag 120 ggacttcaga agagtgtcgc ttccattggc aatacgttga acagtgtcag ccttgctgta 180 gaggcaatac agaagaccgt ggatgaacac aaggcacctt ggagttactg cagggcagtg 240 tggagaccaa tggaagcaac caaatca 267 <210> 18 <211> 271 <212> DNA
<213> Rattus norvegicus <220>
<221> unsure <222> 2, 92, 162, 181, 247-248, 253, 256, 262, 269 <223> a or g or c or t, unknown, or other <220>
<221> misc_feature <223> Incyte template ID No: 700481732F6 <400> 18 gncttattta tgtatgaaaa tgcagaaatc tgtacattcc tcaa.gccagt cctgtcgagc 60 caggtctgtc ccatccttgt acctcaaccc antcccacct ggcc.tgaaca ccccatgaga 120 cagagctggt ctctgggctg gggcccccag gcctgggctg gnca.ggcaga ccctaccccg 180 nagtccactg gctccagtct ccgaggctct cctgggctac aaag~ggggac cacacacacc 240 cagaatnntt tantgnattg gngggcccng g 271 <210> 19 WO 00/127b0 PCT/US99/19768 <211> 283 <212> DNA
<213> Rattus norvegicus <220>
<221> unsure <222> 37, 131, 199, 205-206 , 208, 232-233, 23la, 244-246, 251, 253-254 <222> 261-262, 266, 269, 274-275, 280 <223> a or g or c or t, unknown, or other <220>
<221> misc_feature <223> Incyte template ID No: 700483143F6 <400> 19 ctaaaattaa gatagaagtg aatgagacag atatctngta ac~acactgta ttttcttgtg 60 tgatcagatc tagtgtggtg ggatgataga agttgaactt gcattatt:gc tatgggttaa 120 aatattttgt ntcattaaaa tggcctattg aaatgctttt ct:gttcctat aataaaataa 180 cctgatgaaa aagtaaaana aaaannanaa aaaaaaaggg gc:ggcccccg cnnagggcnt 240 tttnnncccg ngnnttantt nngccnggnc cctnnggggn cc:a 283 <210> 20 <211> 256 <212> DNA
<213> Rattus norvegicus <220>
<221> misc_feature <223> Incyte template ID No: 700484538F6 <400> 20 ctggcctcag cttcctaagt tctgggagtc ggacaggtgt ttgccacaca catggcccac 60 cggggaccta gaacctacag tgaaccgtca cccaggctct gtggatgttc tgcatcctga 120 ggtagacagc ctctaatatc ctgttaggga cctaggacca gagctggggt gcccaggcat 180 gtcccaacat gtcgcatcgg ccacagggat atcggttgaa gtgcatttgg aagtgtgctg 240 ggacgccagc cagctt 256 <210> 21 <211> 272 <212> DNA
<213> Rattus norvegicus <220>
<221> unsure <222> 64, 68; 124, 140, 145, 213, 260, 267, 269 <223> a or g or c or t, unknown, or other <220>
<221> misc_feature <223> Incyte template ID No: 700480077F6 <400> 21 ctgacctgac ccatgattta aggaccgtag tttagcacgg accactgcaa aggcgggcta 60 aggnctgntg ggctaaaggt ctctttgagc ccagtggcta tac~tcacacc ttctttgctc 120 tggnccagga ggcctacttn ttctntactc gtggaatcct gga~atcttaa agataaaaga 180 acctagaaag aaaatcaaac ccactttcct tgngggcaga tc~gtaatatg ggactgagac 240 agcaaacctg gggcttggan aggaccnanc tc <210> 22 <211> 270 <212> DNA
<213> Rattus norvegicus <220>
<221> unsure <222> 40, 44, 46, 114 <223> a or g or c or t, unknown, or other <220>
<221> misc_feature <223> Incyte template ID No: 700060207F7 <400> 22 tacccctgca tgggataccg tttctcgacc ccagtgcacn tg~gntnctgt catcccatga 60 aattgcagca agggcagtct cttttgtggg aacagattaa ctcctacaca tgangtagat 120 tcaacacctg ccaggaaagc agaagcatta cttaagtgtc ctgtgaaggc aaacatcaag 180 tcaattcagc ttatcttgaa gagtggcaaa ccatgaactc ca.aatgtcat tgtgtgaaac 240 tgaacgatgg tcatttcatt ccggtgctgg 270 <210> 23 <211> 250 <212> DNA
<213> Rattus norvegicus <220>
<221> unsure <222> 45, 49-50 <223> a or g or c or t, unknown, or other <220>
<221> misc_feature <223> Incyte template ID No: 700133105F6 <400> 23 ccctcctgta tctgaaccca gcttctcagc tctgagatga gt~gcnggann ggcttcccaa 60 cctatgctca at.accacagg cagcctgcag gagggagaaa tg~ggtaaaat gttccatggg 120 aaatgtctca gaatcgtctc ccccgaatct cctgctaagc tttactgctg ctatggagtg 180 atcatggtcc tcagtgtagc tgtagttgct ctttctgttg ctttgtcagt aaaaatgaca 240 ccacagatct 250 <210> 24 <211> 226 <212> DNA
<213> Rattus norvegicus <220>
<221> misc_feature <223> Incyte template ID No: 700138117F6 <400> 24 gaggattcac tcacatttgc ttcccgctgg ccatgagtga gcagcccttt ctgagtccag 60 agggagccag agggcctcac aacaacagag ggtctcagag ct:ccctggag gaaggctcag 120 ttacaggctc agaggctcgg cacagcttag gtgtcctgaa tc~tgtccttc agcgtcagca 180 accgtgtcgg gccctggtgg aacatcaaat catgccagca gaagtg 226 <210> 25 <211> 265 <212> DNA
<213> Rattus norvegicus <220>
<221> unsure <222> 85 <223> a or g or c or t, unknown, or other <220>
<221> misc_feature <223> Incyte template ID No: 700268788F6 <400> 25 cggaggtgct cccaggcggc tgcactggct cggaggagta gc:aggaggag ctccgcgcag 60 gaacaaacct ggaggcaaac caganggagg caatgtttga at:gactgtaa gaagaccaga 120 cagtgaaaat gtcagccctc aactggaagc cctttgtgta co~gagggctg cctccatcac 180 cgcagaatgt ggtacatttc caattgattt gactaagact cg~gcttcaga ttcaaggcca 240 gacaaatgat gccaagttcc gagag 265 <210> 26 <211> 257 <212> DNA
<213> Rattus norvegicus <220>
<221> unsure <222> 58, 99 <223> a or g or c or t, unknown, or other <220>
<221> misc_feature <223> Incyte template ID No: 700270924F6 <400> 26 ctgggatccc cagggctaat gggcatcctg ttcttgcagc ag~ggcactgt gagaaagnct 60 ctcaccgtga ccaagtttct ctgagtgtcc agccaaccna gg~ctcaccag ctccctccag 120 ctaccgcccg tccatcaggt cagctgccaa ccccaggctg aa.caccaacc ccagctatga 180 gctcctggag gcatgactcc ctcagggcca gcagctccga tcccctccca gtagttatca 240 ttggcaatgg ccctcgg <210> 27 <211> 244 <212> DNA
<213> Rattus norvegicus <220>

<221> unsure <222> 2, 8, 50, 56, 63, 76, 177, 219, 233, 240 <223> a or g or c or t, unknown, or other <220>
<221> misa_feature <223> Incyte template ID No: 700303722F6 <400> 27 gncgaggnca ccaaggtgtt tctgcctcta cttagaaagt ccaaggggan gctggntaac 60 gtnagcagca tggganccat gattccattt cagatgatgg ccgcctacgc ctgcacgaag 120 gcagctataa gcatgttctc agcccgtcat caggcaagag cittccaaatg gggagtnaaa 180 gcgggaccat cattctggag cttcaaacca acatcgtang ctcacaggac agntgggatn 240 aaag 244 <210> 28 <211> 263 <212> DNA
<213> Rattus norvegicus <220>
<221> misc_feature <223> Incyte template ID No: 700502047F6 <400> 28 ggaaatgact ggtctgaagc ggcttggcag cctgagcagt caggtactgc ggctctactg 60 gcactgcctg agggtccaag gactgtggtg attctcatgg aqgaccctga gatttctgca 120 atctgatcag tgtcaaatgc cactggattc gctctgagac tcatgcccta gaggatggcc 180 aaagggctcc tgatgaccta tgccctttgg cttttggggc ccagttggac tacaccacct 240 gtatctggga agggacagcc atc 263 <210> 29 <211> 259 <212> DNA
<213> Rattus norvegicus <220>
<221> unsure <222> 52, .137, 167, 189, 235,254, 256 <223> a or g or c or t, unknown, or other <220>
<221> misc_feature <223> Incyte template ID No: 700502260F6 <400> 29 ggacta.cccc caccatgccc gtgtcattga gactctgatt gtccactatg gnctggtctt 60 tgaggaggag ccagaagaag cagctggcag ccaagagggg gcgtccgcca gtgtgcccag 120 ctggagactg ctgaggncat tgtcttcccc cagcaggagg aggcggncga tggaaaccga 180 gaatcccang tgcatcaatg actcagactc agagctggaa gaggcttctg acctntttcg 240 cctcggacgc cacncnctc 259 <210> 30 <211> 260 <212> DNA
<213> Rattus norvegicus <220>
<221> unsure <222> I40, 158, 161, 170-171, 177, 191, 193, 199, 203, 206-207, 212 <222> 217-218, 220, 224, 226, 231, 238, 243, 246, 248, 253, 255, 258 <223> a or g or c or t, unknown, or other <220>
<221> misc_feature <223> Incyte template ID No: 700142213F6 <400> 30 cacagggttt tccccaagag cacgcctctt tacttcaggg a.attctcgga aactttcagg 60 attcgggggg cttccetggg aggagacgag agaggattag a.agcggacat ccacggcttc 120 ttgtgatgac cacgcctttn gtctttgcta gaactctntg n.gacttcccn nggtganttc 180 taatcacgga ntncacgcna agnttnngga antacgnngn cccntnaaga naaacacntt 240 ttnggngngg ggnanaanct- 260 <210> 31 <211> 288 <212> DNA
<213> Rattus norvegicus <220>
<221> misc_feature <223> incyte template ID No: 700229555H1 <400> 31 caggagtacc actcacaggc cacctggcag gaagagataa gcccccagcc cccgacatcc 60 aggacgcccc gaacctgcca atgtgtgtag ctatacctta ttacctcatc atgtgaaata 120 gccaatcata tgtgaacatg tctatgtgcc tcgtttgaat ccaccaatcc ctgtaactat 180 gcatctgctt ctgtacgcct gcttctgctt ccccaatccc t~ataaaagcc ccatgctgga 240 gctgctgggc gcgcaagtcc tcctaagaga ctgtgtgccc gcagtacc 288 <210> 32 <211> 258 <212> DNA
<213> Rattus norvegicus <220>
<221> unsure <222> 53, 244 <223> a or g or c or t, unknown, or other <220>
<221> misc_feature <223> Incyte template ID No: 700626839H1 <400> 32 gggtgcgcgt ggagttgcgc atgcgccttc ccgccgcgca gc~gcaaaggt ggnggcgctc 60 tggtgaatgg ttggttgctg tgcaagagcg ttttctggct ttaggtggcg aaggcggcct 120 ggccgcgagg tgcagctgct ggtgggcagg tgtactaatg tcaacagact atgagctttc 180 agaatctctg gagagagtac aaagttctgc atgttatggt ac:ctttaatc gggttcatac 240 attngggtgg cacagaat <210> 33 <211> 268 <212> DNA
<213> Rattus norvegicus <220>
<221> unsure <222> 7, 11, 40, 53, 150 <223> a or g or c or t, unknown, or other <220>
<221> misc_feature <223> Incyte template ID No: 700627890H1 <400> 33 gtacaangag ngccggggct tgggtctagt tggaggggan gcagtggcca gtncagggct 60 cagatgagag agttagccga gttaggggca gctactagga tgggggcagg aggagaagcg 120 gggctaacta taaagaagac.tagatttcgn cacagtgggt atgtggaagg cagctttcaa 180 accgcccttg tcaaacaaca cagggccagc agccttcaag accaggctat ccctgccgtc 240 tgctggcatg ggggcacttg taccgtcc 268 <210> 34 <211> 299 <212> DNA
<213> Rattus norvegicus <220>
<221> misc_feature <223> Incyte template ID No: 700059105H1 <400> 34 tcatcacaac ccaactgtgt ggccaaatcc agaggtgttt gacccttatc gatttgcacc 60 agagtcttcc cgacacagcc actcattcct gcccttctca gc~aggagcaa ggaactgcat 120 tgggaaacag tttgccatga atgaactgaa ggtggccgtg gc:cctgaccc tgctccgctt 180 tgagctgctg ccagatccca ccaggatccc aatccccata cc:aagactcg tgttgaagtc 240 caagaatggg atctacctgc gtctcaaaaa gctccaataa tcatgacagc acaagacag 299 <210> 35 <211> 300 <2I2> DNA
<213> Rattus norvegicus <220>
<221> misc_feature <223> Incyte template ID No: 700059610H1 <400> 3S
aaacaacctg actttcttgc gtgtgaggag tgccttttat gc~gaacagca tcatctacaa 60 tatgtcctct gatggccgtt tgtcccgccg ggcctgccag atagctcatg agcacacaga 120 tggagtgatc aaaatgagga aggctcagct gcagaatgag ga~agagcttc agaaggccag 180 gaagaagagg cacttggatt tcctggacat cctgttgttt gc:caaaatgg aggatgggaa 240 gagcttgtct gatgaggacc tgcgtgcaga ggtggacaca ttcatgtttg agggtcatga 300 <210> 36 <211> 296 <212> DNA
<213> Rattus norvegicus <220>
<221> misc_feature <223> Incyte template ID No: 700059630H1 <400> 36 gggtttctct gtatttaccc ctacaagatc cctggatggt gt:ctctgggt tcttccaagg 60 ggccttcctg ctcagtctat ttctggtgct gttcaaggca gt:ccaattct acttacgaag 120 gcaatggctg ctcaaggccc tcgagaagtt ccca.tccacg ccatcccact ggctttgggg 180 ccacgacctg aaggacagag aattccagca ggttcttacg tc~ggtagaga aattcccagg 240 tgcctgctta cagtggctct cagggagcaa aacacgagtc ct:gctctatg accctg 296 <210> 37 <211> 286 <212> DNA
<213> Rattus norvegicus <220>
<221> unsure <222> 204 <223> a or g or C or t, unknown, or other <220>
<221> misc_feature <223> Incyte template ID No: 700062959H1 <400> 37 ggcccatgga gcacacccag gctgtggact atgttaagaa gcagatgacc aagggccgct 60 actcactaga tgtgtggagt aggagctacc accctcccac cc:ctcgctcc ctgtaatcac 120 ctaacttctg ccgacctcca cctctggtgg ttcctgcctg gc:ctggacac agggaggccc 180 agggactgac tcctggcctg agtngtgccc tcctgggccc ctaagcagag tccggtccat 240 tgtatcaggc agcccagccc caaggcacat ggcaagaggg at.tgac 286 <210> 38 ..
<211> 289 <212> DNA
<213> Rattus norvegicus <220>
<221> misc_feature <223> Incyte template ID No: 700606459H1 <400> 38 ggtgagtccc gtgtggagaa aatatacaag taagaccgct acgtgcctgg cgactggaga 60 tgtgatgggg cacagcgcac agagagccat aatggcctca tcgtacaggt ctgggacgct 120 cagcaacacc ccagcaggca ctgcactgtc tagtggacaa gctctgttag caggaagagc 180 ttctctgcgt ctgtccaaga aaggctggtc aaggctccct accacctaca catactgtgg 240 ttggagaaat caaggttcct ggcaaaagag agtagcttca cgggaggca 289 <210> 39 <2I1> 79 <212> DNA
<213> Rattus norvegicus <220>
<221> unsure <222> 39, 48, 66, 68, 72 <223> a or g or c or t, unknown, or other <220>
<221> misc_feature <223> Incyte template ID No: 700608882H1 <400> 39 cttaacgctc ctgccacgcc gcctccgccc gtgcaatgnc tcagtagncg gcgatctacg 60 tacgtntncc cngccccgt 7g <210> 40 <211> 248 <212> DNA
<213> Rattus norvegicus <220>
<221> unsure <222> 8, 21, 24, 35, 40, 52, 78, 9D, 104, 137, 169, 209, 220 <223> a or g or c or t, unknown, or other <220>
<221> misc_feature <223> Incyte template ID No: 700483988H1 <400> 40 tttagttnca atcatggagg nctntcaggt gaggncctan ct:cccaaagc cngcgctgag 60 tctacaactt ctcctaanag gtgttccggn cggcgttggg gt,cnctgcgg aggcggctaa 12D
atcggccgca gtttctncca tggttgcgcc cgctgtgttg cg~cgctctnc gtaagaacaa 180 gacccttcgc tatggagttc ccatgttgnt gctggttgtn ag~tggttctt ttggtcttcg 240 cgaatttt 248 <210> 41 <211> 352 <212> DNA
<213> Rattus norvegicus <220>
<221> unsure <222> 28, 324; 337 <223> a or g or c or t, unknown, or other <220>
<221> misc_feature <223> Incyte template ID No: 700501033H1 <4D0> 41 ctctctgcct atgttctgag gttggagnct ttattacaga agctggtgca gaaaggagca 60 attgagaaag aagttgtgaa tcaggcccga ctagaccaag tcattgctgg ggcaatccac 120 aagtcagttc gaagagagct tggactgcca gaaggtagcc ctgccccagg cttattgcag 180 ttgctgacac tgataaaaga taaggaggca gcagaggaag a!~gtccttct tcaggccgaa 240 ttagaaggac atttcacttg acccaagacc agcaaggctg t~catgagcag aacatgatgg 300 aggagctcat agaagtgatc agcncatccc ctttggnctg ccaagtaatt gc 352 <210> 42 <211> 233 <212> DNA
<213> Rattus norvegicus <220>
<221> misc_feature <223> Incyte template ID No: 700137747H1 <400> 42 gtttctccat agcctcagac cccacatcag tatcctcttg ci::acttggag gagcacgtga 60 gcaaagaggc taaccatcta atcagcaagt tccagaagct gatggcagag gttggccact 120 tcgaaccagt caaccaggtg gtggaatcgg tggctaatgt catcggagcc atgtgttttg 180 ggaagaactt ccccaggaag agcgaggaga tgctcaacct c<~tgaagagc agc 233 <210> 43 <211> 243 <212> DNA
<213> Rattus noxvegicus <220>
<221> unsure <222> 33 <223> a or g or c or t, unknown, or other <220>
<221> misc_feature <223> Incyte template ID No: 700141708H1 <400> 43 tgggcagaaa ggaagccctg cagagcatca gangcccagc tagagggaca acacagagga 60 gtaatttgct gacagacctg cagggatgga cctgctttca gcactcacac tggaaacctg 120 ggtcctcctg gcagtcgtcc tggtgctcct ctacggattt gc~gacccgca cacatggact 180 tttcaagaaa caggggattc ctgggcccaa acctctgcct ttatttggca ctgtgctgaa 240 tta 243 <210> 44 <211> 295 <212> DNA
<213> Rattus norvegicus <220>
<221> unsure <222> 286 <223> a or g or c or t, unknown, or other <220>
<221> mist feature WO 00/127b0 PCT/US99/197b8 <223> Incyte template ID No: 700302454H1 <400> 44 gcgggccgtg ggtgatctgg tcggtaccgg agagcgcagg ttc~tatcacc aacatggggg 60 actctcacga agacaccagt gccaccatgc ctgaggccgt.ggcagaagaa gtgtctctat 120 tcagcacgac ggacatggtt ctgttttctc tcatcgtggg ggt:cctgacc tactggttca 180 tctttagaaa gaagaaagaa gagataccgg agttcagcaa gat:ccaaaca acggccccac 240 ccgtcaaaga gagcagcttc gtggaaaaga tgaagaaaac ggc~aangaac ttatc 295 <2I0> 45 <211> 286 <212> DNA
<213> Rattus norvegicus <220>
<221> misc_feature <223> Incyte template ID No: 700304405H1 <400> 45 cggaagtgaa ccaaggcact gagcggcatc taatgcacct gga~gttggac atctcagact 60 ccaagatcag gtatgaatct ggagatcacg tggctgtgta ccc:agccaat gactcagccc 120 tggtcaacca gattggggag atcctgggag ctgacctgga tgt:catcatg tctctaaaca 180 atctcgatga ggagtcaaac aagaagcatc cgttcccctg ccc:caccacc taccgcacgg 240 ccctcaccta ctacctggac atcactaacc cgccacgcac caa~tgt 286 <210> 46 <211> 311 <212> DNA
<213> Rattus norvegicus <220>
<221> unsure <222> 299 <223> a or g or,c or t, unknown, or. other <220>
<221> misc_feature <223> Incyte template ID No: 700306096H1 <400> 46 gataggaaaa taattttatt taggtttttt aaaaaagtta actttcacat ataaatttag 60 acttaaagat tacagtgtat attttccaaa aggagcgccc ctgaagggtg gccagacaag 120 ctcgccgagt gggcacaggg acactcgctc cagaaggagc tcaggtggaa gcgctttctt 180 taatcttcca cagtggccct tccctgttcc tcaccgggcc tatgactggt aagaaaaccc 240 acaaccatca tttggggcaa cagcatctca ctagatggga ataagaacat gtctaggang 300 aaagcacaag c 311 <210> 47 <211> 307 <212> DNA
<213> Rattus norvegicus <220>
<221> mist feature <223> Incyte template ID No: 700325693H1 <400> 47 gtgccctcac gcagcttaat gtggcctttt cccgggagca ggcccacaag gtctatgtcc 60 agcaccttct gaagagagac agggaacacc tgtggaagct gatccacgag ggcggtgccc 120 acatctatgt gtgcggggat gctcgaaata tggccaaaga tgtgcaaaac acattctatg 180 acattgtggc tgagttcggg cccatggagc acacccaggc tgtggactat gttaagaagc 240 tgatgaccaa gggccgctac tcactagatg tgtggagcta ggagcttacc aacctcccac 300 ccctcgg 307 <210> 48 <211> 300 <212> DNA
<213> Rattus norvegicus c220>
<221> unsure <222> 21, 49, 199, 226 <223> a or g or. c or t, unknown, or other <220>
<221> misc_feature <223> Incyte template ID No: 700059571H1 <400> 48 ctgtgctcct gagtgcaagc naggcattcc tccaagacac tgcgggtcng agcagggact 60 gttcacgctg gtgccctgtg aactctggtg gaggtcagcc aacagctgct gtgtctgagt 120 tgctgagagg agagagaatg gcttgcactg agttttcttt ccacgtgcca agtctggagg 180 agctcgcaga agttttgcng aaggggctaa aggacaactt tc~ctcntgtc caggtctctg 240 tggtcgactg cccagattta acaaaggagc catttacttt cccgtaaaag gcatctgtgg 300 <210> 49 <211> 314 <212> DNA
<213> Rattus norvegicus <220>
<221> unsure <222> 13 <223> a or g or c or t, unknown, or other <220>
<221> misc_feature <223> Incyte template ID No: 700060610H1 <400> 49 gcaagattga ggnggagaag gacaacctga agtctgagtt cc;atctggag aacttggctg 60 tctgtgggtc taacttgttt acggcaggca ccgagacaac cagcaccacc ctgagattcg 120 ggctcctgct ccttatgaag tatccagagg tgcaagccaa ac~ttcatgag gaacttgacc 180 gtgtgattgg acgccaccaa ccccccagca tgaaggacaa gatgaagctg ccttataccg 240 atgctgtatt gcatgagatt caaagataca tcactctcct tc;cttccagt ctgccccatg 300 ctgtggtcca ggac 314 <210> 50 <211> 312 <212> DNA
<213> Rattus norvegicus <220>
<221> unsure <222> 78 <223> a or g or c or t, unknown, or other <220>
<221> misc_feature <223> Incyte template ID No: 700063128H1 <400> 50 cggtcggtac cggagagcgc aggttgtatc accaacatgg gggactctca cgaagacacc 60 agtgccacca tgcctgangc cgtggctgaa gaagtgtctc tattcagcac gacggacatg 120 gttctgtttt ctctcatcgt gggggtcctg acctactggt tcatctttag aaagaagaaa 180 gaagagatac cggagttcag caagatccaa acaacggccc cacccgtcaa agagagcagc 240 ttcgtggaaa agatgaagaa aacgggaagg aacattatcg tattctatgg ctcccagacg 300 ggaaccgctg ag <210> 51 <211> 248 <212> DNA
<213> Rattus norvegicus <220>
<221> unsure <222> 64-65 <223> a or g or c or t, unknown, or other <220>
<221> misc_feature <223> Incyte template ID No: 7001396S6H1 <400> 51 caaaatacaa caaggagata aaagtcatac agtttgtgct gctggcttat tagctctgca 60 tggnngaggg gccatggtaa gttgccaagg cattcagata to<~atgtaat taagatgcca 120 tgtttgcttg cagtaatgaa gttataatca gaaactgcta aac~tatgata aaaacagtga 180 ttgtttatgc acttatggaa gacaaagtga agtgatgtgg tttcttcaga acaggtgatg 240 cactgagg <210> 52 <211> 115 <212> DNA
<213> Rattus norvegicus <220>
<221> misc_feature <223> Incyte template ID No: 700141348H1 <400> 52 gtaaaagatg tggtccagag aacgtaggaa catgcctgga gac~acctaat gtgctcttgt 60 tctgcaaacc catgggcatt atttccctct ccgctcaaga gct:catactg gaagc 115 <210> 53 <211> 249 <212 > DNA
<213> Rattus norvegicus <220>
<221> misc_feature <223> Incyte template ID No: 700182318H1 <400> 53 agagtttcct tttgctcccc aacctgtagt tctaagttca acaaaacagt catcaacaaa 60 agtgacggag gcttccatca gtgtcagggc tctgtgcaga cccagaatcc ctgttcccta 120 tgtcatgttc cagcattgta tagcacggtt ccatgtcaca a.acagaaagg tcaggaacac 180 tgaggtctgt gaatgtcact gctgcagcga ggtcatgtca ctcctctgtc tactctgtca 240 gtgtcttac. 249 <210> 54 <211> 296 <212> DNA
<213> Rattus norvegicus <220>
<221> unsure <222> 22 <223> a or g or c ox t, unknown, or other <220>
<221> misc_feature <223> Incyte template ID No: 700225376H1 <400> 54 agcaagccta tttctgactg gnctgctgtg cagaatctag accactggca gtgggtgaca 60 gcccagttga ggttaatcga agtctcgtcg caggctctgc tgtaagtctg gcctcttggc 120 ctcacatctt ctttgtggga tccttcccta tctccagctt cctcagetgg tcagggagat 180 ttggtccaga actagaagcc ttaataatct gagcaggtaa gagaggagta aaatgtacag 240 tcttggacat tgactaaagg gtcctgcaga ggatatcaag gtaagtggct tggagg 296 <210> 55 <211> 169 <212> DNA
<213> Rattus norvegicus <220>
<221> misc_feature <223> Incyte template ID No: 700225757H1 <400> 55 gctttctggg caagtctatg ttgccctagc tgacccagaa tttgctatat agactattct 60 gtctcaaact cacagaaatt ctcctgcctg tgcctcctga gcgagcacca ggattaaagg 120 cgtgaatcgc tgtccccgtc ttttttcttt cttcttttaa t~aacccact 169 <210> 56 <211> 19I
<212> DNA

<213> Rattus norvegicus <220>
<221> unsure <222> 190 <223> a or g or c or t, unknown, or other <220>
<221> misc_feature <223> Incyte template ID No: 700268788H1 <400> 56 cggaggtgct cccaggcggc tgcactggct cggaggagta gcaggaggag ctccgccgca 60 ggaacaaacc tggaggcaaa ccagaaggag gcaatgtttg aatgactgta agaagaccag 120 acagtgaaaa tgtcagccct caactggaag ccctttgtgt acggagggct ggcctccatc 180 aaccgcggan t 191 <210> 57 <211> 249 <212> DNA
<213> Rattus norvegicus <220>
<221> unsure <222> 45, 118, 128, 163, 245 <223> a or g or c or t, unknown, or other <220>
<221> misc_feature <223> Incyte template ID No: 700270924H1 <400> 57 tgggatcccc aggggctaat gggcatcctg ttcttgcagc agggnactgt gagaaagtct 60 ctcaccgtga ccaagtttct ctgagtgtcc agccaaccca ggctcaccag ctccctcnag 120 ctaccgcncg tccatcaggt caactgccaa ccccaggctg aanaccaaac ccagctatga 180-gctcctggag gcatgactcc ctcagggcca gcagctccga tccctcccag tagtgatcat 240 gggcnaggg 249 <210> 58 <211> 294 <212> DNA
<213> Rattus norvegicus <220>
<221> unsure <222> 19, 32, 35, 104, 131, 188, 220 <223> a or g or c or t,'unknown, or other <220>
<221> misc_feature <223> Incyte template ID No: 70029166iH1 <400> 58 actagcttct ccagctccnt ctttcecgag angcngcagg gacctcggcc tccagcttac 60 cgggcggatc gaagcagcgg tcgggatggt actgctgggc tt:gntgcagt caggcggctc 120 WO 00/127b0 PCT/US99119'768 ggtgctcggg naggcgatgg agcaggtgac aggaggcaac ctgctttcca cgctgctcat 180 cgcctgcncc ttcacgctta gccttgtcta cctgttccgn ctcgcagtgg gccacatggt 240 ccagctgccc gctggagcga aaagtccgcc atatatttac tctccaattc cgtc 294 <210> 59 <211> 304 <212> DNA
<213> Rattus norvegicus <220>
<221> misc_feature <223> Incyte template ID No: 700301979H1 <400> 59 gatatattaa tcaaaaagaa aggaccacga ctcatgacct cccatcttcc catgcatctt 6.0 ttctccaagt ctctcttcag ttccaaggcc aaggtgatct ai~ctcgtcag aaatcccaga 120 gatgttcttg tttctggtta ttatttctgg ggtaattcaa ci~cttgcgaa gaagccagac 180 tcactgggaa cttatgttga atggttcctc aaaggaaatg ttctatatgg atcatggttt 240 gagcacatcc gtgcctggct gtccatgcaa gaatgggaca a<atcttgtt actgtactat 300 gang 304 <210> 60 <211> 293 <212> DNA
<213> Rattus norvegicus <220>
<221> misc_feature <223> Incyte template ID No: 700302770H1 <400> 60 gtagccactc taactagggg cgtgctgaga caagaccacc tc:attcctct gctgcttttc 60 agacaggact gtcctgccga cccaccatga tccaggctgc acagttcctt ggctgtatct 120 tactgtcctc ggtgaccgcc tttccatgga agactcagga tc~gtggcctg ccccatcagc 180 cagctggcac agaaactgag cctacacaac tgctctacag caagagtcct cctccgacct 240 ccagtacctg tcggaacctc ctaagcatgg cgcccctgcc cc:ctgtagtc ctc 293 <210> 61 <211> 174 <212> DNA
<213> Rattus norvegicus <220>
<221> misc_feature <223> Incyte template ID No: 700303111H1 <400> 61 caacagcaaa cgtgcgacca actcttcggc tagtgaatct ct:aagccgcg aagagtgctt 60 tgaagtagct ttaggtggaa gatgtcagaa agtaactcgg cagagggtag cgacagaagc 120 gaggagcagg tgtctggtgc taaagtcatc gcccaggccc ta~aaaacgca agat 174 <210> 62 <211> 273 WO 00/127b0 PCT/US99/197b8 <212> DNA
<213> Rattus norvegicus <220>
<221> unsure <222> 52, 139, 249 <223> a or g or c or t, unknown, or other <220>
<221> misc_feature <223> Incyte template ID No: 700303390H1 <400> 62 ctcagatggc aggcatggca tgcatgggat cttgttccct gagacaaagg cngatgcaga 60 gggcatgtga ataaatcatg aggggcccac agcaggccag caggccatag ctgacctcat 1.20 tctggaagtg agagttgang agaccccagc tgggacagaa aaggtaccac gcctataacc 180 atggcctaac cgagggccag cagtggcagc ctccctgaaa gc~gacttcca gtccatccac 240 aggcaccgna gaaccagcaa gacatagcca gcc 273 <210> 63 <211> 279 <212> DNA
<213> Rattus norvegicus <220>
<221> misc_feature <223> Incyte template ID No: 700303722H1 <400> 63 gtgactctga gtgtttgagc aggtaacttc tacctttgca ccactatcgc aacaggtcca 60 aaggttccaa aggagctggc aggacactca gacaagatcc acaggcttca ggtgtgccta 120 gtcctggagt tcagaaagac ggaggcagct gaatgtggtg ct:gaaccaac aacatctagc 180 tacaagggga gccactcctc cacccagcga ctgtgactgt tcacacaggt ctgaatttcc 240 tgttggtatt cacaaagatg ctttttattt ttaacttct 279 <210> 64 <211> 275 <212> DNA
<213> Rattus norvegicus <220>
<221> misc_feature <223> Incyte template ID No: 700306343H1 <400> 64 gagaaaggcc accacctagc taggtgaggt gtgccagcat ggrtcctgggg gtctcactgt 60 ccccagccct gggacgctgg ttccgccatg caatcccttt cg~ctatcttc acgctgttac 120 ttctttatat cagtgtatgg ctcttccatg agtggccctt tg~agttgcca gctcaaagaa 180 ctcagcagtc cggcctgtgg gaactcaagc tctcttctcc tt.ctccagcc ctcacctctc 240 tgcttcctgt cacctcaggt gttttacaag gctga 275 <210> 65 <211> 294 <212> DNA

<213> Rattus norvegicus <220>
<221> misc_feature <223> Incyte template ID No: 700306615H1 <400> 65 catccgtggg ctggctcacg ccattcgcct gttcctggag tatacagaca caagctatga 60 ggacaagaag tacagcatgg gggatgctcc cgactatgac ac~aagccagt ggctgagtga I20 gaagttcaaa ctgggcctgg acttccccaa tctgccctac ttaattgatg ggtcacacaa 180 gatcacccag agcaatgcca tcctgcgcta ccttggccgg aagcacaacc tttgtgggga 240 gacagaggag gagaggattc gtgtggacgt tttggagaac caggctatgg acac 294 <210> 66 <211> 283 <212> DNA
<213> Rattus norvegicus <220>
<221> unsure <222> 2 <223> a or g or c or t, unknown, or other <220>
<221> misc_feature <223> Incyte template ID No: 700330359H1 <400> 66 gnggcccaat ggcccetgag taaaaggtgg tcactgagag tc:ctaaggcc cgagtaggaa 60 catgcggctt agagccagtg tcgtgaccca gaacgtccac tcttgtacag gtagatgagg 120 aggtgttcgg gtgcccgcag gcggtatccc gcctggcttt cc~ccctagcc tttctgcaac 180 gcatggacat gaagccgctg gtggtcctgg gactgccggc cccgacggcc ccttccggct 240 gtctctcctt ctgggaagct aaggcacagc ttgctcagag ci:g 283 <210> 67 <211> 263 <212> DNA
<213> Rattus norvegicus <220>
<221> misc_feature <223> Incyte template ID No; 700368974H1 <400> 67 tccttagctg ggggcggggg gggcagtctg ctactatctg aacgaattta atgtgggagt 60 catgccttat acaacacagg aaattaatgt gtgatctaat gc:gtgatcta tgacttatta 120 caatacagga atttaatgtg tgagccatgc cttcaaaaca tc~tctagaat ttctggaatt 180 ggccggaagt caacagggat tgcttattta acctttcaaa tc:actcattg tgactagggc 240 acatggtctt gcgcttgcta tga 263 <210> 68 <211> 269 <212> DNA
<213> Rattus norvegicus <220>
<221> unsure <222> 129, 133, 153, 163, 165 <223> a or g or c or t, unknown, or other c220>
<221> misc_feature <223> Incyte template ID No: 700373118H1 <400> 68 gtttgaagca gggcgtaggg aaaagcggga ttaaagagta ct:acctttat tagctccttc 60 cctccagaat aggtgcaaat ccctccccat gcccatttcc tc;ccacctgg ggtaaggatg 120 tggcactgnc agnctgtcag cccactgact ttnagtcttc ac~ntngcagt ctgggcaaat 180 accagcgagc tctgttgaac caagaccagg ccttcagagc at:ctgaacca ctgtggcctt 240 ctctcctcag ccttcactgt ggcttttgc 269 c210> 69 <211> 288 c212> DNA
<213> Rattus norvegicus c220>
<221> unsure c222> 159 <223> a or g ar a or t, unknown, or other c220>
c221> misc_feature c223> Incyte template ID No: 700375521H1 <400> 69 gcagccatgg atcgcgggga ggaacctctg tccgcgaggc cc~gcgctgga gaccgagagc 60 ctgcgattcc tgcacgt:cac agtgggctcc ctgctggcca gcaatggctg gtacatcctc 120 ttcagctgcg tccttctcta cattgtcatc cagaagctnt cc:ctgcgact gagggcttta 180 aggcagaggc agctggacca agctgaggct gttctggagc ct:gatgttgt tgttaagcga 240 caagaggctt tagcagctgc tcgtttgaga atgcaggaag at:ctgaat 288 c210> 70 <211> 280 -c212> DNA
<213> Rattus norvegicus c220>
<221> unsure <222> 16, 84, 96, 112-114, 118, 171, 226, 228, 236, 240, 267 c223> a or g or c or t, unknown, or other <220>
c221> misc_feature <223> incyte template ID No: 700461546H1 c400> 70 tgaacaaact tctganaact tagttgacag tgttttgagt caactgaaaa aagcatgact 60 tttggaatct ctgaatgcct tggntctcag tattancact ct:attgaatt tnnntctnat 120 taaagtatgt agttttttag acttttttcc tgacagtatt at:gtaatttt ntggcgtggg 180 tagatgggag tgtcgcttgt atgttaccat acagctgaca tgtatntntt gtctantctn 240 attatcttag tagtttcatg ctgtggnatg taccataacc 280 <210> 71 <211> 271 <212> DNA
<213> Rattus norvegicus <220>
<221> unsure <222> 25, 64, 70, 82, 102, 155 <223> a or g or c or t, unknown, or other <220>
<221> misc_feature <223> Incyte template ID No: 700480077H1 <400> 71 ctgacctgac ccatgatgta ~agggnccgta ggggagcatc accactgcaa aggctgacta 60 aggnctgttn ggctaaaggt cnctttgaag cccagtgtct anagtcacac cttctttgct 120 ctgggcccag gaggcctact tcttcttttt ctcgnggaat cctggaatct taaagataaa 180 agaacctaga aagaaaatca aacccacttt ccttgtgggg cagatggtaa tatgggactg 240 agaacagcaa acctggggtc ttggagagga g 271 <210> 72 <211> 210 <212> DNA
<213> Rattus norvegicus <220>
<221> unsure <222> 187 <223> a or g or c or t, unknown, or other <220>
<221> misc_feature <223> Incyte template ID No: 700480949H1 <400> 72 gggcagaggt ccagggaata agggaggctt ctaccaatga ttttgtttaa tggtgcttga 60 cagagatatt gtatggttct ctgagagctc ccctgaaaac cttacctcca accacacaag 120 ggttcctccc agagagcgct cgctgggcag caaggacaca ctcccatatt gccaagcata 180 tcaagtnccc aaagattggc agaaaattcg 210 <220> 73 <211> 256 <212> DNA
<213> Rattus narvegicus <220>
<221> unsure <222> 70 <223> a or g or c or t, unknown, or other <220>
<221> misc_feature <223> Incyte template ID No: 700483259H1 <400> 73 gtgacgtaca tggaaaacaa agcctacggg gacaggctca ac~ccgcagac agcagcaagt 60 aaagcgcctn cggccctgaa gcatggcagc tatcccttcc a<~cggctcgc tcgtggctac 120 ccatgactac tatcggcgta agtagcccct cgccagcccc gcccagggct ggcccagggc 180 tctgtggctg acccgcctcc ccttcccagg acgtctgggc tcctcgtcca gcaacagctc 240 cggcggaagt gcagag 256 <210> 74 <211> 259 <212> DNA
<213> Rattus norvegicus <220>
<221> unsure <222> 219 <223> a or g or c or t, unknown, or other <220>
<221> misc_feature <223> Incyte template ID No: 700483475H1 .
<400> 74 ctctcgtact tcggcaatgg ctggattccc accgtcatca cc~gcctttgt ccttgctacc 60 tcccaggccc aagctggatg gctacaacat gattatggcc acctttctgt ctataagaaa 120 tccatatgga accacattgt ccacaagttt gtcattggcc acataaaggg tgcctccgcc 180 aactggtgga accatcgaca tttccagcac catgcgaanc caacatcttc cacaaggacc 240 ccgacataaa gagcctgca 25g <210> 75 <211> 264 <212> DNA
<213> Rattus norvegicus <220>
<221> misc_feature <223> Incyte template ID No: 700498995H1 <400> 75 gacagtagat gcccccaaag ctctagtaga tgatagtgtg gqggctgtgt gcggctccta 60 cctgtgctgt tcattcacag tgcagtttaa gggagcaggc gc:cactgcat tccttggctg I20 tgccctgagg gtgcttgctg ctttatatag taacagtcaa tt:aaggtttc tttcaggaag 180 agaaaaggga tggttttgag gggctcagaa aataggattc ac~tgtgtaac ataacaggta 240 ggttgtcggc acatgctgat atcc 264 <210> 76 <211> 271 <212> DNA
<213> Rattus norvegicus <220>

taaagtatgt agttttttag acttttttcc t <221> unsure <222> 218, 228, 255, 270 <223> a or g or c or t, unknown, or other a220>
<221> misc_feature <223> Incyte template ID No: 700504333H1 <400> 76 gtttattttg acacagacat ggacaaagcg atggagcgct at:gtctctat gcccaaggaa 60 aaggctccag aacacattcc ccttctcttc attgccttcc catcaagcaa ggatccaacc 120 tgggaggacc gattcccaga GCgatccaca atgactgtgc tggtacccac ggcctttgaa 180 tggttcgagg agtggcagga ggagcctaag ggcaagcnaa gt:gttgcntt ggaaccctca 240 aaaaaacttc ccggnaaccc tttatggggn a 271 <210> 77 <211> 167 <212> DNA
<213> Rattus norvegicus <220>
<221> unsure <222> 11-12, 17, 21, 24, 48, 66, 72, 96, 128, 135, 162, 166 <223> a or g or c or t, unknown, or other <220>
<221> misc_feature <223> Incyte template ID No: 700505040H1 <400> 77 caacaatctt nngtggnctg nctntctgga actgggcatc at:cagctnat gctgccatac 60 gcctgntgga gngccgtggg gtgaaggtcg cccgtnccct gqtgggtacc ttcatgtcag 120 cactaganat gcgtngtgtt tcccttactt tgatgcttgt gnatgna 167 <210> 78 <211> 267 <212> DNA
<213> Rattus norvegicus <220>
<221> unsure <222> 5, i8, 26, 39, 90, 92, 122-123, 132, 137, 145, 152, 160, 168, 171 <222> 173-174 , 186-187, 213 <223> a or g or c or t, unknown, or other <220>
<221> misc_feature <223> Incyte template ID No: 700505423H1 <400> 78 ggggncttct gtgaggcnct gatacncatc gaggctgtna tt;cagccagg ccacatgaag 60 ccccaagatg ggtggctttt cctgtatgan tnagtacaga tatatccatg gccggggaat 120 tnngactggc anggtcncca gggancacca gncagctttn tc;aagaantc ntnnggttcc 180 cttggnntca caggaaccta ttacctttca tgnggtctgg gc~ttctggat ttagggtctt 240 tgggacagtc ccagttagaa gccttgg 267 <210> 79 <211> 267 <212> DNA
<213> Rattus norvegicus <220>
<221> unsure <222> 14, 20, 22, 24, 81, 248, 253 <223> a or g or c or t, unknown, or other <220>
<221> misc_feature <223> Incyte template ID No: 700510534H1 <400> 79 tgaaagcgta aggncttgcn tntnagaggc tctgtagtga gtactgtttg cctataaggg 60 aagtggaaca accgagacac ncgcacttct ttcgagtgtt aaggagcctg ggaggagcag 120 gcagccgctt gctttgagca tgctcaggtg gggctgtccg cc;gctgtggg gaaggcaccc 180 tgcagcaggg cttcctgccc cacctctcca ttgtagtagt gt:ccagatct cagaaacgca 240 gcttgaancc agnttcaaag gtaccag 267 <210> 80 <211> 291 <212> DNA
<213> Rattus norvegicus <220>
<221> misc_feature <223> Incyte template ID No: 700513027H1 <400> $0 gggaggtttt aaaggccata ttgccaacct caccgaaagg tt.tcaggaac ccgaggaagt 60 gttaatgtac aactcaccac ttcacgccac ccgaggctga ag~ttgacgtt gccttttaag 120 cctttttaca tacactggcc atttcagaaa attctcaaca at.aatgtctg ccttcgagtt 180 taagtcatgg tgttttttag aattgacttg aaatgaaaat at.cacaaagt gaatatatca 240 gctggtgatc gagtgactga aacccccctg.gtctgcggtt ga.ccagttca g 291 <210> 81 <211> 273 <212> DNA
<213> Rattus norvegicus <220>
<221> misc_feature <223> Incyte template ID No: 700528082H1 <400> al ataaaagtga aaactgggca agggcagggg gctgggcgtg aaccgcttac tagataatgt 60 tctctaaaaa ttggctctga aaaccctgtt tgtgtattcg ttttatgagt gcttaaaaat 120 ggtgtgacca gggcatggtc actgtcattg gaacagcaac atgcttgctg gtcacattgg 180 aatggggaaa tgtgaagaaa gctggacatc aggcctgcgg cacccatttc tttgtatgaa 240 agtgttgtgt acaaaccccc cactaatcat ttt 273 WO 00112760 PCT/US99/19768 ' <zlo> e2 <211> 268 <212> DNA
<213> Rattus norvegicus <220>
<221> unsure <222> 68, 121, 165, 174, 182 <223> a or g or c or t, unknown, or other <220>
<221> misc_feature <223> Incyte template ID No: 700528I76H1 <400> 82 caaggccctc agggaatcag aggagccagc ctgatccctg gtctctggag tcttaaaaca 60 agtgtgtntt tgcaggtagt cctagttggg tgtcgggggg aggctgccag gcctggcatg 120 ngacattagg caggaagcca ctctggatga ttgtgcacat g;agancctag tcanggaggg 180 anggttttaa ggagaggact tagaatacaa gtgagaagcc a~~ccgaggaa agggaaccaa 240 gtcctcagaa tagaaggcta tactggct 268 <210> 83 <211> 289 <212> DNA
<213> Rattus norvegicus <220>
<221> misc_feature <223> Incyte template ID No: 700534427H1 <400> 83 ' aaaacaggca agactttgga gaaagcagac caggtatgat gc,~ccactttg ccaccaacag 60 cccacacttc ccagcaacct gtaaacatag aggacgaaga t<~ggatcctg gatgagtatg 120 accagtacag cctggcccaa tcttatgtcg tcggtggagg tcggaaagga cgtaccaaga 180 gagaagctgc tgccaacacc aaccgcccca gccctggtgg gcatgagagg aagctgctga 240 ccaagttcca gaactctgaa aggaaaaagg cctggcgctg a<lacagagc 289 <210> $4 <211> 290 ~-<212> DNA
<213> Rattus norvegicus <220>
<221> unsure <222> 58, 157 <223> a or g or c or t, unknown, or other <220>
<221> misc_feature <223> Incyte template ID No: 700535328H1 <400> 84 ggtctgacca agtgagaaag acagcagggg cacccaggcc tc:agacactc tggcgtantc 60 ccaaagaaag atggccacag cccagctccc tggtaccaag ct:gtcatccc taaactctgc 120 tctgtgcccc ttgtgggcag acgttaatca agccctngcc ctatctgatg ggcccctcca 180 tcccgggaac actaaaaggt agtcttactg tccaccaccc tacacctgtt ttcataagtt 240 atgcacaaat gcgaacagct gagacagaga tggagaagtt cttcgttttg 290 <210> $5 <211> 275 <212> DNA
<213> Rattus norvegicus <220>
<221> unsure <222> 17 ' <223> a or g or c or t, unknovun, or other <220>
<221> misc_feature <223> Incyte template ID No: 700607183H1 <400> 85 cacagcccct accagcncac cctccataac tgcaccaaga g<~atctatcc aacacctccc 60 tgagcaggag gagcctgaag actccaaggg aaagagtcct g<~ggaaccct ttcctgtgca 120 gctggatcta accacaaacc cacagggtga cacactggat gi~ctccttcc tctacctgga 180 gcctgaggaa aagaaactgg tggtcctgcc tttccctggg aaggaacagc gctcccctga 240 gtgcccgggg cccgaaaagc aaagaacccc ctgat 275 <210> 86 <211> 285 <212> DNA
<213> Rattus norvegicus <220>
<221> misc_feature <223> Incyte template ID No: 700607235H1 <400> 86 ctgaagaccc accatgtctc tgctgactac tgtacta.ctt ct:ctggggtt tcattctggg 60 cccagcaact gacacagcct gtatattcaa ggaagcctcg gaaaacagtc ccttgcccag 120 gccctggctt tctgccaatc cagtgccctg gatcacacct ggcctgagga cattcctgct 180 gtgccagggg acagtgcggg atgtagtctt catgctgagg c<<ggaaggag atgatggttt 240 cctggcgata 'gtccaacaga tgtttttctg gagggagctg gaccc 285 <210> 87 <211> 260 <212> DNA
<213> Rattus norvegicus <220>
<221> unsure <222> 246-247 <223> a or g or c or t, unknown, or other <220>
<22i> misc_feature <223> Incyte template ID No: 700607396H1 WO 00/127b0 PCT/US99/197b8 <400> 87 ggccaccaag atggcggcgc ccagcggacg gtgcgcgagg ttcgtcagct gacttgttct 60 cggagctgtg gccgcgaccc gcttctacct gtcccgagtg accagagctc agtgaccagt 120 ccttatagtc gaaagcaggg tttttactgc tgaggacctg gacccgctgg gaggcttgcc 180 atggtaacag aacaggaggt agaggccata gggaaaaccc tagtggactc cacgcagccc 240 ctgcannccc gcttccgtgc 260 <210> 88 <211> 181 <212> DNA
<213> Rattus norvegicus <220>
<221> unsure <222> 27, 180 <223> a or g or c or t, unknown, or other <220>
<221> misc_feature <223> Incyte template ID No: 700607505H1 <400> 88 caaagaaaga aaacactcct ccgaggnccg cagcaaaggc a~~agaaagat ctgcaggatg 60 accttcatta cagcaggtgt tatattttat cttttttgcc t~ccgtttcta gtgaatgtat 120 cactaaggtc ttcaaagaca tcagctttca aggaggtgcc t:aag>ractgt ttccacacan 180 <210> 89 <211> 280 <212> DNA
<213> Rattus norvegicus <220>
<221> misc_feature <223> Incyte template ID No: 700607713H1 <400> 89 aattgagggg taaacatgtc tttgtgaaat atatgttctt tt~acaatact ttgtactaat 50 ttacgtggaavttattatttg tttctcattg gagatattta tt:cagcctca atggcctttc 120 aggaactcct gaatcaggta ggaggcctag ggagattcca gatccttcag atggtttttg 180 ttgtcttcac cagtgttatt gtggtacctc atattataat agagaactta ctgcagccat 240 tcccagtcat cgctgctggg ttcctatcct cgacaatgtc 280 <210> 90 <211> 267 <212> DNA
<213> Rattus narvegicus <220>
<221> unsure <222> 6, 77, 128, 143, 146 <223> a or g or c or t, unknown, or other <220>

WO 00/127b0 PCT/US99/197b8 <221> misc_feature <223> Incyte template ID No: 700607873H1 <400> 90 gaaganacac caaagctcac tcactcttca ggttctcact gaacctactg tatcggaagg 60 gacttcacct cccagangtc catttttatg aagactgttg agacagcttt. ccagaaacta 120 gaaccatntg gaagatagac ctnggngtat tcctgtgcgg attatcttga ttacgttaat 180 taattctgga tgggactagg ctaaagtgtc atcatgattt tccattaaca aggtgcacag 240 atgctacaaa tggctgggag aaatcct 267 <2zo> 91 <211> 258 <212> DNA
<213> Rattus norvegicus <220>
<221> unsure <222> 21, 109 <223> a or g or c or t, unknown, or other <220>
<221> misc_feature <223> Incyte template ID No: 700607972H1 <400> 91 gaggctaagc ntgtgcctcc tggtctctct ggggcagtcg c~~cgcgcgcc aagacctttc 60 gctgacctca gcgtcccgct gctgcgcaag gaagggcggg gccactgcng tctggacagc 120 gtccgaaggc agcgagtcct ctggaggccg ccgtagtgca gaggagtcgg ttgtcacgtg 180 acccaaggtt agaccatggc ttccaccaag ccgctgtctc gcttctggga gtggggcaag 240 aatatcgttt gcgtgggg 258 <210> 92 <211> 276 <212> DNA
<213> Rattus norvegicus <220>
<221> misc_feature <223> Incyte template ID No: 700608519H1 <400> 92 caccacactg catctgccct acatgccacc ttacaccatc at:ctatttcc cctcccgagg 60 tgtggcctca gcgtttt:caa gatgaagggc acaagccata gt:cactcctg gggaacccct 120 caacactggt gctggaggga tgtggccaag accacgttgg gc~gcaagacc gagacttggg 180 gcgggactac aattgtggtt ggtggggcca ggactgacct ctaagcctcc ataggcagct 240 acactgtctg tcacttttcc tccttccctg tgccgg 276 <210> 93 <2T1> 295 <212> DNA
<213> Rattus norvegicus <220>
<221> unsure <222> 35 <223> a or g or c or t, unknown, or other <220>
<221> misc_feature <223> Incyte template ID No: 700608661H1 <400> 93 cttagtccct gtactctgag ggtaagcctc atcgntcagg atctattgct gctgcttctc 60 cagctggctt ctgtagagac tgacagagac aactttgcag g<~taaggtag ctatcaagat 120 gctccatttg cgaagttcac agatgctgca gatgttggag a<~ctccttaa ggaaatacct 180 tcctgagtcc ttaaaggttt atgggactgt cttccacatg aaccagggag ccccattcaa 240 gctcaaggct ctggtggaca agtggcctga tttaatacag tggttgtccg tcctc 295 <210> 94 <211> 293 <212> DNA
<213> Rattus norvegicus <220>
<221> unsure <222> 16, 179 <223> a or g or c or t, unknown, or other <220>
<221> misc_feature <223> Incyte template ID No: 700609074H1 <400> 94 ggcgtggagt tggagnagag cgtcaggcgc ctccgggaga acfitttcatgg aaaagtgtcc 60 cccaagaagg caggggctct tatgaggaag tttggcagcg a<:cacactgg agttgggcgc 120 tctatcgtgt acgggctcaa gcagaaagat ggacaggagc tgagcaacga tttggacgnc 180 caggacccac cagaggacat gaagcaggac caagatatcc ac~gcagtagc cacctctctg 240 ttgcccctga cgcaagccaa tcttcgaatg ttccaaagag cc:caagatga cct 293 <210> 95 <211> 288 <212> DNA
<213> Rattus norvegicus <220>
<221> unsure <222> 66, 138, 152, 236, 242, 252-253, 279 <223> a or g or c or t, unknown, or other <220>
<221> misc_feature <223> Incyte template ID No: 700609967H1 <400> 95 ctgcctcgca gccccgagcg cgcgcctctc cagctcccgc tc:cggcttcc ccaaccaggc 60 ttattntggc tcccgacccg gtgcagaccc ctgacccggc ct:ccgcccag ctccgccaaa 120 tgcgctactt tacttggnag gaggtggcgc angctccggg ac~ggagaagg agcgatggct 180 cgtaatcgac cggaaggtgt acaacatcag cgacttcagt tc:gccgccac ccgggnggct 240 cncgggtcat cnnccactag ctggtcagga tgccacggna tc:ctttgt 288 <210> 96 <211> 164 <212> DNA
<213> Rattus norvegicus <220> , <221> misc_feature <223> Incyte template ID No: 700625315H1 <400> 96 gttagagcag ttacactgaa ccaaagtgac tgagtttgta cagacggtaa tccgtaccaa 60 gcacactcac tgtcctgatc tgaacaccca gcaaggttca tgtccgtgct aagtttgcag 120 cattgtgttc ttttgcattc tttttttact tttattaaag gi~tc 164 <210> 97 <211> 225 <212> DNA
<213> Rattus norvegicus <220>
<221> unsure <222> 28, 59, 65, 73, 79, 84, 88 <223> a or g or c or t, unknown, or other <220>
<221> misc_feature <223> Incyte template ID No: 700627089H1 <400> 97 cgcggcggct gcagcaggcc accatggnag agcttcagga g<fitgcagatc actagaggng 60 aagcnattgt tgncaggtnt ggcnttantg gttgagtcta tcactacagt gggttccctg 120 tttgctctgg catcatactc cateatcttc ctcaagcttt tcacctaccg ggatgtcaat 180 ctgtggtgcc gccagcgaag ggtcaaggcc aaagctgtgt ct~gca 225 <210> 98 <211> 265 <212> DNA
<213> Rattus norvegicus <220>
<221> unsure <222> 62, 264 <223> a or g or c or t, unknown, or other <220>
<221> misc_feature <223> Incyte template ID No: 700629293H1 <400> 98 atgaccttta acttttctaa aaatgtgaag ttttgtactt at:atatatca gctaaagtat 60 tntagcattc tttagtgtac ttagtttgat gccactttta gt:gtttttgt tgcttttgtc 120 tgatttttat gaatgttcat tttaagactc cttgttgaaa tc~ggacagtt tcgttctttg 180 ataagcccga gaagaggatt cccttgggtg ttgacctcct ct:gcatgatg tgcccaagca 240 tctgaactgc aaccaaggcc tttnc 265 WO 00/12760 ' PCT/US99l19768 <210> 99 <211> 95 <212> DNA
<213> Rattus norvegicus <220>
<221> misc_feature <223> Incyte template ID No: 700643961H1 <400> 99 agtataacca ggggccatct gaaagttgtt ctctagccag ataagccact atgagcggta 60 agcatcagtg ctaacgcaga aacttcctga gcagc 95 <210> 100 <211> 307 <212> DNA
<213> Rattus norvegicus <220>
<221> unsure <222> 8, 20, 21, 23, 47, 302 <223> a or g or c or t, unknown, or other <220>
<221> misc_feature <223> Incyte template ID No.: 700061625H1 <400> 100 gggaaganac actggcttan nanttggttc tgagggaagc tcactgngtg gatacatatt 60 tataggattt gggtgcaacg aactgtgtga ctagttcagt tc:aattcagg gagcaggcag 120 aaaccagcag gtattagaag agatgttcta tatacagagt tcagaggcac tgcagattct 180 gaagaattcc ctaaggaagc acctccctga gtccttaaag gtaatgggac tgtctccaca 240 tgaaccaggg aaacccattc aagctcaagg ctgtggtgga caagtggctg atttaatact 300 gntgtta 307 <210>101 <211>97 <212>DNA

<213>Rattus norvegicus <220>
<22i> unsure <222> 48, 90 <223> a or g or c or t, unknown, or other <220>
<221> misc_feature <223> Incyte template ID No.: 700062809H1 <400> 101 ccctgagagt ctccaaaatg tttcagtctg ttataagaac cccattanct cactaaagct 60 tgcactggct gactcctgga cggggttccn gaatgtg g7 WO 00!12760 <210> 102 <211> 214 <212> DNA
<2I3> Rattus norvegicus <220> .
<221> misc_feature <223> Incyte template ID No.: 700239104H1 <400> 102 gagatgttcc ctgtcatcga acagtatgga gacattttgg taaaatactt gaggcaagag 60 aaaggcaaac ctgtccctgt gaaagaagtg tttggtgcct a.cagcatgga tgtgatcacc 120 agcacatcat ttggagtgaa tgttgattcc ctcaacaacc cgaaggatcc ttttgtggag 180 aaagccaaga agctcttaag aattgatttt tttg 214 <210> 103 <211> 265 <212> DNA
<213> Rattus norvegicus <220>
<221> misc_feature <223> Incyte template ID No.: 700139953H1 <400> 103 aggaagccct gcagagcatc agaggcccag ctagagggac aacacagagg agtaatttgc 60 tgacagacct gcagggatgg acctgctttc agctctcaca ctggaaacct gggtcctcct 120 ggcagtcgtc ctggtgctcc tctacggatt tgggacccgc acacatggac ttttcaagaa 180 acaggggatt cctgggccca aacctctgcc tttttttggc actgtgctga attactatat 240 gggtttatgg aaattcgatg tggag <210> 104 <211> 306 <212> DNA
<213> Rattus nozvegicus <220>
<221> unsure <222> 2, 61, 68, 111, 139, 263, (296)..~(298), 305 <221> unsure <222>
<223> a or g or c or t, unknown, or other <220>
<221> misc_feature <223> Incyte template ID No.: 700289281H1 <400> 104 ancagatccg ggcactggag agggagctgc aagcaggagc agtcaagagt gtggtcagaa 60 ncaccgtnag tggaccagca gggccggctt tttctaccat. ggcggcccaa ngctatggct 120 attaccgcac tgtcatatnc acagccatgt tcggaggcta cagcctttac tacttcaacc 180 gcaaaacctt ctcttttgtc atgccctcct tggtggatga gatcgctctg gacaaggacg 240 atttgggggc tcatcacgag canccagtcg gcagcctacc~ catcagcaag tttgtnnncg 300 gggtnt WO 00!12760 PCT/US99I19768 <210> 105 <211> 183 <212> DNA
<213> Rattus norvegicus <220>
<221> misc_feature <223> Incyte template ID No.: 700303922H1 <400> 105 ggcagcattg atccttatgt atatctgccc tttggaaatg gacccaggaa ctgcattggc 60 atgaggtttg ctctcatgaa tatgaaactc gctctcacta aagttctgca aaacttctcc 120 ttccagcctt gtaaggaaac acagatacct ctgaaattaa gcagacaagg acttcttcaa 180 cca 183 <210> 106 <211> 290 <212> DNA
<213> Rattus norvegicus <220>
<221> unsure <222> 56 <223> a or g or c or t, unknov~m, or other <220>
<221> misc_feature <223> Incyte template ID No.: 700305783H1 <400> 106 ctaacagtga atacatagct gcgatcctgg aactcagctc cctcatagtg aaacgncaac &0 gccagccctt cctgtacctg gacttcctgt attgcctcac tgctgatggg cggcgcttcc 120 gcaaggcctg cgacgtggtg cacaacttca cagatgctgt catcagggag agacgcagca 180 ccctcaatac ccagggcgtt gatgaattcc taaaggccag g~gctaagact aaaactttag 240 actttattga tgttctcttg ctggccaagg atgagcatgg gaaggggctg 290 <210> 107 <211> 177 <212> DNA
<213> Rattus norvegicus <220>
<221> misc_feature <223> Incyte template ID No.: 700329969H1 <400> 107 gctatatcag gaggggaccc atgctgtgtc cttctgagat c~taacaggat taaccaatat 60 gtaaactaga ggaagtggtt ggcctgcact gggcaagccc tctaggactc catccaagaa 120 agaccagttg gtgttgctct agaggcaaag aaacccataa ggagctggca gtaaaac 177 <210> 108 <211> 188 <212> DNA
<213> Rattus norvegicus WO 00/12760 PCTI(JS99/19768 <220>
<221> unsure <222> 114, 116 <223> a or g or c or t, unknown, or other <220>
<221> misc_feature <223> Incyte template ID No.: 700368493H1 <400> 108 aaagcttccc aatctgtgtg ctcacttggg aggatggcat taggagccag ggctggccat 60 gggtacctta ctttcctccc tggggtatgc ccaggagaat ggagaaaaaa aaangnttta 120 aagaaaaaat attttaaatt tgatgctggc ctttttcaat tgtattgagt aaaagtgttc 180 aagttgtc 188 <210> 109 <211> 255 <212> DNA
<213> Rattus norvegicus <220>
<221> unsure <222> 156, 157 <223> a or g or c or t, unknown, or other <220>
<221> misc_feature <223> Incyte template ID No.: 700376694H1 <400> 109 ttatgattat caattttaca taacattaat attatatcaa acctccttaa gaaaatgagt 60 atggatgttc acagtatgtt tgatttttat ctacaagaat g,aatctgatt cagaatgctt 120 ttcagctgac atacagagca ctaaatactt taaggnnaac aataggtctg aatetcttaa 180 gaattctcag tctctatggg atgtagggac gcattataaa tgcattaatc cttatagtca 240 atcctgtgcc tagga 255 <210> 110 <211> 284 <212> DNA
<213> Rattus norvegicus <220>
<221> unsure <222> 16, 25, 54, 63, 68, 70, 80, 141, 154, 2:L0, 275 <221> unsure <222>
<223> a or g or c or t, unknown, or other <z2o>
<221> misc_feature <223> Incyte template ID No.: 700483803H1 <400> 110 gaggaacgcc gccgcntcgc tcggnatcct acaccaatca gc~aagctgct gtcnagccat 60 ggnggganan gagaagccan ctcaagaggc tgacgtggaa cc;catggtaa catcaggggc 120 WO 00112760 PCT/US99/1976$
ctcagaagca gtgccaaggg ngctttctgg agancctcag aacatctctg atgtagatgc 180 cttcaacttg ctcctggaga tgaaactgan acgacggcgt gaggtcccaa ccttccatgt 240 actgtgaccc agctagtggc cgaggatggc agcanggtgt atgt 284 <210> 111 <211> 258 <212> DNA
<213> Rattus norvegicus <220>
<221> misc_feature <223> Incyte template ID No.: 700502844H1 <400> 111 ggcagacctt agcagattct ggatgccatc agtgactgaa gccattaagg agactcggct 60 ggagtagcag ctaagaggac agagagacaa gggctacgag gcagcaatat aaacagatct 120 ggtgttgctg agatttgaga cgaaggtttc ccatggcttc ttttcacatc cgccagttcc 180 aggagaggga ctatgaacag gtcgtggata tgttctccag g~ggaatgaag gaacacatcc 240 ccactgcctt ccgccact 258 <210> 112 <211> 250 <212> DNA
<213> Rattus norvegicus <220>
<221> misc_feature <223> Incyte template ID No.: 700503415H1 <400> 112 gtagctttcc ccttttgctg gcacagaagt ctgtccatct gcaagcgctt tggaacacag 60 actgcctgga gccaccttcc tttgggagac cttcctgcct c~agctgtcgt cctgtgtcgt 120 cattcactaa agctcctgac gtcagattaa gcaagcagtg atgggttaca ttagagacaa 180 gccgcagaga taaggcctgt tgctgtttcg cagataatga t~gagttttaa ttacccactg 240 gtttgtatgg 250 <210> 113 <211> 278 <212> DNA
<213> Rattus norvegicus <220>
<221> unsure <222> 40, 44, (53)...(55), 60, 69, 72, 74, 15:9, 234 <221> unsure <222>
<223> a or g or c or t, unknown, or other <220>
<221> misc_feature <223> Incyte template ID No.: 700514914H1 <400> 113 ccactgcagc gccccccccc aaagatggaa agattctgcn ti~ancttcat atnnncttan 60 aacatttgna cncnattctt taactttaga atctccccta gagcctgttc ttctttaaac 120 accctttatg ctggagtagg atgatggctg agtttcttna a<~agagctta aatatagagt 180 cacaaacatg agatagatgc ctgccgccca ctctttccac aaactcgaga accnctttgt 240 gcacgcagct gccatggaag gaaatcctgg ggcttctt 278 <210> 1I4 <211> 308 <212> DNA
<213> Rattus norvegicus <220>
<221> misc_feature <223> Incyte template ID No.: 700519169H2 <400> 114 cccaatcttt taagactttt cataatgatg ttaagaccag ggcagactat ctactggcca tggactgcag ccaggagatg ccctgcccct cctgggacct gcacaccacc tctctgggga 120 acttgacaaa ggtccctaag gctaagggag gtctccttcc t<ictaggtcc ctgactttga 180 ctctgtggtt ctctaggaac cgtgtgcaca cttgtctctg ttgtaaccac aaagggcagt 240 agcacctagc atgtcatgtc ctgccccggc tgcttgcctc ccacccaccc aggattctct 300 gggctggc 308 <210> 115 <211> 124 <212> DNA
<213> Rattus norvegicus <220>
<221> unsure <222> 34, 53, 87, 109, 122 <223> a or g or c or t, unknown, or other <220>
<221> misc_feature <223> Incyte template ID No.: 700535905H1 <400> 115 cctacctctg gtggaaaaag tacatcactc aggngcagct g<~tccagttt gtngctgaca 60 atcatccaga-ccagctgcgg ggtcatntgg ccgtgctcct tc:cctctcng gtggctgtac 120 tncc 124 <220> 116 <211> 262 <212> DNA
<213> Rattus norvegicus <220>
<221> unsure <222> 148 <223> a or g or c or t, unknown, or other <220>
<221> misc_feature <223> Incyte template ID No.: 700593984H1 <400> 116 gggaaagtgt gttctgaggg ccctgtgggg ccaaggggga ccagcctcac attccacacg 60 tgCgCCaCtC tgcttggagc ctatttattt tgtatttatt tgaacagagt tatgtcctaa 120 ctatttttat agatttgttt aattaatncc ctgtcatttt caagttcatt ttttttattc 180 atatttatgt tcatggttga ttgtacctcc tgtcaccagc tg~gtggggca.ggggagacaa 240 ggtagaaagt ggccacagag tg 262 <210> 117 <211>~267 <212> DNA
<213> Rattus norvegicus <220>
<221> unsure <222> 36, 37, 223 <223> a or g or c or t, unknown, or other <220>
<221> misc_feature <223> Incyte template ID No.: 700607844H1 <400> 117 ctcgatcgtc cagaccccac ggcgtcacca tgctgnncca tg~atcaggaa ctcactgttc 60 gggagcgtgg agacgtggcc ttggcaggtt ttaagcaccg gg~ggcaagga agacgtctcc 120 tatgaggaaa gagcctgcga agggggaaag tttgctactg tg~gaagtgac agacaaacct 180 gtggatgagg ctctccggga agcaatgccc aagatcatga ag~ncgtgggg ggcaccaatg 240 acaaaggagt cggcatggga atgacag 267

Claims (8)

What is claimed is:

1. A method for detecting or diagnosing the effect of a test compound or molecule associated with increased or decreased levels of a nucleic acid molecule in a mammalian subject comprising:
a) treating a mammalian subject with a toxic compound or molecule;
b) obtaining a sample containing nucleic acids from the mammalian subject treated with the toxic compound or molecule;
c) contacting the sample with a microarray comprising a plurality of nucleic acid molecules comprising SEQ ID NOs: 1-117, or a fragment thereof, under conditions for the formation of one or more hybridization complexes;
d) detecting the hybridization complexes, wherein the presence, absence or change in amount of the hybridization complex, as compared with the hybridization complexes formed from nucleic acid molecules from an untreated mammalian subject, is indicative of a metabolic response.
to the toxic compound or molecule;
e) measuring the level of nucleic acid molecules in a sample from a mammalian subject treated with a test compound or molecule using the method of steps (c) and (d); and f) comparing the level detected in step (e) to a level of nucleic acid molecules present in normal or untreated biological sample in which an increase or decrease in the level of nucleic acid molecule as compared to normal levels indicates a toxicological response.

2. The method of claim 1 wherein the toxic compound or molecule is selected from hypolipidemic drugs, n-alkylcarboxylic acids, n-alkylcarboxylic acid precursors, azole antifungal compounds, leukotriene D4 antagonists, herbicides, pesticides, phthalate esters, phenyl acetate, dehydroepiandrosterone sulfate, oleic acid, methanol and their corresponding metabolites, acetaminophen and its corresponding metabolites, benzo(a)pyrene, 3-methylcholanthrene, benz(a)anthracene, 7,12-dimethylbenz(a)anthracene, and their corresponding metabolites.

3. The method of claim 1 wherein the sample is a tissue selected from the group consisting of liver, kidney, brain, spleen, pancreas, and lung.

4. The method of claim 1 wherein the test compound which elicits the metabolic response is a compound with previously unknown metabolic response.

5. The method of claim 1 wherein the test compound or molecule which elicits the metabolic response induces at least a 2-fold change in the amount of the hybridization complexes formed with at least one of the nucleic acid molecules of the sample.

6. An isolated and purified nucleic acid molecule selected from SEQ ID NOs:1-117, or a fragment thereof.

7. A method of using the nucleic acid molecule of claim 6 to screen a library of molecules or compounds to identify at least one molecule or compound which specifically binds the nucleic acid molecule, the method comprising:
a) combining the nucleic acid molecule of claim 6 with a library of molecules or compounds under conditions to allow specific binding; and b) detecting specific binding, thereby identifying a molecule or compound which specifically binds the nucleic acid molecule.

8. The method of claim 7 wherein the library is selected from DNA molecules, RNA
molecules, peptide nucleic acids, artificial chromosome constructions, peptides, and proteins.